NZ615210B2 - Azole derivative - Google Patents

Azole derivative Download PDF

Info

Publication number
NZ615210B2
NZ615210B2 NZ615210A NZ61521012A NZ615210B2 NZ 615210 B2 NZ615210 B2 NZ 615210B2 NZ 615210 A NZ615210 A NZ 615210A NZ 61521012 A NZ61521012 A NZ 61521012A NZ 615210 B2 NZ615210 B2 NZ 615210B2
Authority
NZ
New Zealand
Prior art keywords
group
hydroxy
difluoro
compound
tetramethylcyclohexyl
Prior art date
Application number
NZ615210A
Other versions
NZ615210A (en
Inventor
Shoichi Kuroda
Yusuke Oka
Naoya Ono
Yoshinori Sekiguchi
Yoshihisa Shirasaki
Tetsuo Takayama
Fumihito Ushiyama
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority claimed from PCT/JP2012/056624 external-priority patent/WO2012124750A1/en
Publication of NZ615210A publication Critical patent/NZ615210A/en
Publication of NZ615210B2 publication Critical patent/NZ615210B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Provided are: a novel compound which binds to FKBP12 or a pharmaceutically acceptable salt thereof; and a novel therapeutic agent which contains the compound or a pharmaceutically acceptable salt thereof and is useful for the prophylaxis or treatment of alopecia. Specifically provided is a compound which is represented by formula (1) or a pharmaceutically acceptable salt thereof. (In formula (1), R represents a group represented by formula (2) or formula (3).) Compounds of the invention include: (S)-1-(2-(5-((3,4-dimethoxyphenoxy)methyl)-1,3,4-thiadiazol-2-yl)pyrrolidin-1-yl)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone, (S)-1-(2-(5-((3,4-dimethoxyphenoxy)methyl)-4H-1,2,4-triazol-3-yl)pyrrolidin-1-yl)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone, (S)-1-(2-(5-((3,4-dimethoxyphenoxy)methyl)oxazol-2-yl)pyrrolidin-1-yl)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone, (S)-1-(2-(5-((3,4-dimethoxyphenoxy)methyl)thiazol-2-yl)pyrrolidin-1-yl)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone, and (S)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)-1-(2-(5 -((pyrimidin-5-yloxy)methyl)isoxazol-3-yl)pyrrolidin-1-yl)ethanone. which is represented by formula (1) or a pharmaceutically acceptable salt thereof. (In formula (1), R represents a group represented by formula (2) or formula (3).) Compounds of the invention include: (S)-1-(2-(5-((3,4-dimethoxyphenoxy)methyl)-1,3,4-thiadiazol-2-yl)pyrrolidin-1-yl)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone, (S)-1-(2-(5-((3,4-dimethoxyphenoxy)methyl)-4H-1,2,4-triazol-3-yl)pyrrolidin-1-yl)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone, (S)-1-(2-(5-((3,4-dimethoxyphenoxy)methyl)oxazol-2-yl)pyrrolidin-1-yl)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone, (S)-1-(2-(5-((3,4-dimethoxyphenoxy)methyl)thiazol-2-yl)pyrrolidin-1-yl)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone, and (S)-2,2-difluoro-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)-1-(2-(5 -((pyrimidin-5-yloxy)methyl)isoxazol-3-yl)pyrrolidin-1-yl)ethanone.

Description

DESCRIPTION AZOLE DERIVATIVE TECHNICAL FIELD The present invention relates to novel compounds that bind to FKBP12 or pharmaceutically acceptable salts f, as well as agents for preventing or treating alopecia that contain such novel compounds or pharmaceutically acceptable salts thereof as an active ingredient.
BACKGROUND ART Alopecia sts itself in various types including male pattern alopecia, alopecia senilis, alopecia areata, and alopecia in postmenopausal women. While alopecia is not life- threatening in many cases, the e is cosmetically ssing and often involves mental pain; under the circumstances, effective agents for preventing or treating alopecia are desired.
Hairs are born again through three stages, the anagen, catagen, and telogen phases (hair . One hair cycle usually takes a period of two to seven years to complete and if something abnormal occurs to shorten this period, hair growth is arrested before reaching maturity. As a consequence, more hairs will fall out to result in a lower hair density or the ess per hair will decrease. Factors that upset the rhythm of hair cycle include androgens such as testosterone and dihydrotestosterone, radiation, medicaments such as anticancer drugs, aging, and stress.
Studies using many diverse compounds are being made with a View to creating eutics for alopecia, and the immunosuppressant FKS06 (tacrolimus), for example, has been reported to have a recognizable hair—development stimulating effect in a pluralilty of animal models (see Patent nt 1 and Non-Patent Document 1.) The action of FK506 has been confirmed in models of alopecia areata which is considered an autoimmune disease (see Non-Patent Documents 2 and 3), as well as in hair pment tests using normal mice and models of alopecia medicamentosa (see Non—Patent Documents 4 and 5.) However, due to its immunosuppressing action, FK506 has high risk for side-effects, so there is desired a safer compound that is effective as a eutic for alopecia without presenting the immunosuppressing action.
A plurality of compounds that bind to immunophilin FKBP12 (an FK506 binding protein with a molecular weight of 12 kDa) t exerting the immunosuppressing action have recently been found (see Patent Documents 2-10.) Some of those derivatives have been disclosed to show a hair-development stimulating action (see Patent Documents 11 and 12.) Other derivatives, however, have not been ed to show any hair-development stimulating action and much s unclear about the relationship between the activity of binding to immunophilin FKBP12 and the hair-development stimulating activity. What is more, the ed FKBP12 binding compounds are not disclosed to have the same azole structures as specified in the present invention.
CITAITON LIST PATENT LITERATURE Patent Document 1: Japanese Patent No. 2925285 (EP – A – 423714) Patent Document 2: Patent nt 3: Patent Document 4: Patent Document 5: Patent Document 6: WO 45006 Patent Document 7: Patent Document 8: Patent Document 9: JP 2004-123556 A Patent Document 10: JP 2004-123557 A Patent Document 11: WO 98/55090 Patent Document 12: (US 2010/0022604A) NON-PATENT LITERATURE Non-Patent nt 1: Yamamoto et al., “J. Invest. Dermatol.”, 102, 160-164, 1994 Non-Patent Document 2: Freyschmidt-Paul et al., “Eur. J. Dermatol.”, 11, 405-409, 2001 Non-Patent Document 3: McElwee et al., “Br. J. Dermatol.”, 137, 491-497, 1997 Non-Patent Document 4: Jianga et al., “J. Invest. Dermatol.”, 104, 523-525, 1995 Non-Patent Document5: Maurer et al., “Am. J. Pathol.”, 150, 1433-1441, 1997 SUMMARY OF INVENTION TECHNICAL PROBLEM An object of the present invention is to find novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof and e new therapeutics useful in preventing or treating alopecia, or to provide the public with a useful alternative.
SOLUTION TO PROBLEM The present ors found that compounds represented by the following formula (1) or ceutically acceptable salts thereof can solve the aforementioned problem and this g has led to the accomplishment of the present ion. ingly, the present invention relates to: (I) A compound represented by formula (1) [where R1 represents either the following formula (2) or (3) ring A represents either one of the rings represented by the following formula (4) [00 1 5 ] ('4) X represents -(CH2)m-X1-(CH2)n'; X1 represents a bond, -o—, —NRaC(=O)-, -C(=O)NRb—, —NR°S(=O)2 —, or -S(=O)2NRd-; Ra, Rb, R°, and Rd which may be the same or different each represent a hydrogen atom or a CH; alkyl group; m and n which may be the same or ent each represent an integer of 0-3; R2 represents an aryl group, a aryl group (said aryl or heteroaryl group may be substituted by 1-3 substituent groups selected from the group consisting of a halogen atom, a C1_6 alkyl group, and a C1_6 alkoxy group (said CH, alkyl group or C1-6 alkoxy group may be tuted by 1-3 substituent groups selected from the group consisting of a halogen atom and a hydroxy group)), a 1,3-benzodioxolanyl group, an indolyl group, a morpholyl group, a hydroxy group, a C1_6 alkyl group (said C1_6 alkyl group may be substituted by 1-2 hydroxy groups), an amino group, a H, alkylamino group, a di-C1_6 alkylamino group, a C1_6 alkoxy group, a CH, alkylsulfonyloxy group, a pyridonyl group, or a pyrimidinonyl group] or a pharmaceutically acceptable salts thereof; (I’) The compound or pharmaceutically acceptable salt thereof according to (I), wherein R2 ents an aryl group, a heteroaryl group (said aryl or heteroaryl group may be substituted by 1—3 tuent groups selected from the group consisting of a C1_6 alkyl group and a C1_6 alkoxy group (said C1-6 alkyl group or C14, alkoxy group may be substituted by 1-3 substituent groups selected from the group ting of a halogen atom and a hydroxy group)), a 1,3 -benzodioxolanyl group, an indolyl group, a lyl group, a hydroxy group, a C1-6 alkyl group (said CH; alkyl group may be substituted by 1-2 hydroxy groups), an amino group, a mono-C14, alkylamino group, a di—C1_6 alkylamino group, a C1-6 alkoxy group, or a C1_6 alkylsulfonyloxy group; (II) The compound or pharmaceutically acceptable salt thereof according to (I) or (I’), wherein X is a bond, -CH2‘O-, -CH2-, —(CH2)2—, -(CH2)3—, —O-, -CH2-NHC(=O)-, -CH2-NHC(=O)-CH2-, or -CH2-NHS(=O)2—; (III) The compound or pharmaceutically able salt thereof according to (I) or (I’), wherein X is -CH20— 0r —CH2-; (IV) The compound or pharmaceutically acceptable salt thereof according to any one of (I) to (III) and (I’), wherein R1 is a (2); (V) The compound or pharmaceutically acceptable salt thereof according to any one of (I) to (IV) and (I’), wherein ring A is either one of the rings of the following formula (5): far. 0 (VI) The nd or pharmaceutically acceptable salt thereof according to any one of (I) to (V) and (1’), n R2 is a phenyl group, a pyridyl group, a pyridazinyl group or a pyrimidyl group (said phenyl group, pyridyl group or pyrimidyl group may be substituted by 1-3 halogen atoms or methoxy groups), a pyridonyl group, or a pyrimidinonyl grOUP; (VII) The compound or pharmaceutically acceptable salt f according to (VI), wherein R2 is a phenyl group or a pyridyl group (said phenyl group or pyridyl group may be substituted by 1-3 methoxy groups); (VIII) The compound according to (I), which is (S)—1—(2-(5-((3,4-dimethoxyphenoxy)methyl)isoxazol-3 —y1)pyrrolidin— l -yl)—2,2-difluoro(1 - hydroxy-3,3,5,5-tetramethylcyclohexy1)ethanone, (S)-2,2—difluoro—2—(1 -hydroxy—3 ,3 ,5 ,5 -tetramethylcyclohexyl)—l -(2-(5-((pyridin-3 - yloxy)methyl)isoxazol-3 -yl)pyrrolidin— 1 —yl)ethanone, (S)-2,2-difluoro(1 —hydroxy-3 ,3 ,5,5—tetramethylcyclohexyl)- 1 —(2-(5-((3 ,4,5— trimethoxyphenoxy)methyl)isoxazolyl)pyrrolidin- l -yl)ethanone, (S)-N-((3 -(1 -(2,2-difluoro(1 xy-3 ,3 ,5 ,5 -tetramethylcyclohexyl)acety1)pyrrolidin—2- yl)isoxazoly1)methy1)benzamide, (S)—N—((3 -(1 -(2,2-difluoro(1 -hydroxy-3 ,3 ,5 ,5-tetramethylcyclohexy1)acetyl)pyrrolidin-2— y1)isoxazolyl)methy1)benzenesulfonamide, (S)— 1 -(2-(5-((dimethylamino)methyl)isoxazol-3 -yl)pyrr01idin- l -y1)-2,2-difluoro(1 - y-3,3,5,5-tetramethylcyclohexyl)ethanone, (S)-3 -(1 -((cyclohexylmethy1)su1fonyl)pyrrolidin—Z—y1)(3 ,4— dimethoxyphenoxy)methy1)isoxazole, (S)—1-(2—(5-((3 ,4-dimethoxyphenoxy)methyl)-1 ,3 ,4—oxadiazoly1)pyrrolidiny1)-2,2- o(1 -hydroxy-3 ,3 ,5 ramethylcyclohexyl)ethanone, (S)—2,2-difluoro(1 -hydroxy-3 ,3 ,5 ramethy1cyclohexyl)— 1 -(2-(5—(phenoxymethy1)- 1,3 ,4-oxadiazolyl)pyrrolidin—l —yl)ethanone, (S)—N—((5—(1 -(2,2-difluoro(1 xy-3 ,3 ,5 ,5 -tetramethylcyclohexyl)acety1)pyrrolidin y1)-1 ,3 ,4-oxadiazolyl)methy1)benzamide, (S)-l-(2-(5-((dimethylamino)methyl)-1,3 ,4-oxadiazol—2-y1)pyrrolidinyl)-2,2-difluoro(l - hydroxy—3,3,5,5-tetramethylcyclohexyl)ethanone, (S)(2—(3 -((3 ethoxyphenoxy)methyl)-1,2,4-oxadiazoly1)pflrolidiny1)-2,2- difluoro-Z-(l -hydr0xy-3 ,3 ,5 ,5—tetramethy1cyclohexy1)ethanone, (S)(2-(5 -((3 ,4-dimethoxyphenoxy)methyl)—1,-methy1-1H—pyrazol-3 —y1)pyrrolidin— 1 -y1)—2,2- difluoro-Z-(l -hydroxy—3 ,3 ,5 ,5 -tetramethylcyclohexyl)ethanone, (S)—1—(2-(3 -((3 ,4-dimethoxyphenoxy)methyl)isoxazol-5 -y1)pyrrolidin—1-y1)—2,2-difluoro(1— hydroxy-3 ,3 ,5 ,5—tetramethy1cyclohexyl)ethanone, (S)-1 -(2-(5-((3 ,4-dimethoxyphenoxy)methyl)—1H—pyrazol-3 -y1)pyrrolidin—1 -yl)-2,2—difluoro- 2-(1 -hydroxy-3 ,3 ,5 ,5-tetramethylcycIohexy1)ethanone, (S)— 1 -((3 ,4-dimethoxyphenoxy)methyl)-1 ,3 adiazol-2—y1)pyrrolidin-' 1 -y1)-2,2- difluoro-Z-(l -hydroxy-3 ,3 ,5 ,5 —tetramethylcyclohexy1)ethan0ne, (S)(2-(5—((3,4-dimethoxyphenoxy)methyl)—4H-1 ,2,4-triazol-3 -y1)pyrrolidiny1)-2,2- difluoro-Z-(l -hydroxy-3 ,3 ,5 ramethy_lcyclohexyl)ethan0ne, (S)(2-(5-((3 ethoxyphenoxy)methyl)— 1 -methy1—1H-1 riazol-3 -y1)pyrrolidin yl)-2,2-difluoro(1 -hydroxy-3 ,3 ,5,5-tetramethy1cyclohexy1)ethanone, (S)—1-(2-(5-((3,4-dimethoxyphenoxy)methyl)0xazoly1)pyrrolidinyl)-2,2—difluoro(1 - hydroxy-3 ,3 ,5 ,5 -tetramethy1cyclohexy1)ethan0ne, (S)—1-(2-(5 -((3 ,4-dimethoxyphenoxy)methyl)thiazoly1)pyrrolidin—1 -yl)-2,2-difluoro-2—(1 - hydroxy—3 ,3 ,5 ,5-tetramethylcyclohexyl)ethanone, (S)-2,2-difluoro—2-(1-hydroxy-3 ,3 ,5 ,5-tetramethylcyclohexyl)(2-(5- (phenoxymethyl)isoxazol—3-y1)pyrrolidin—1-y1)ethanone, (S)-2,2-difluoro(l -hydroxy-3 ,3 ,5 ,5 -tetramethylcyclohexyl)— 1 -(2-(5 -((pyrimidin-5 - yloxy)methy1)isoxazol-3 -y1)pyrr01idin— 1 -yl)ethanone, (S)((3 -(1-(2,2-difluoro(1-hydroxy-3,3 ,5,5-tetramethylcyclohexyl)acety1)pyrr01idin y1)is0xazol-5—y1)methy1)pyrimidin-4(1 H)—one, (S)-2,2-diflu0ro(1 xy-3 ,3 ,5 ,5 -tetramethylcyclohexy1)(2-(5-((pyrimidin-4— yloxy)methy1)isoxazol—3—y1)pyrr01idin-1 -yl)ethanone, (S)-2,2—difluoro-1—(2-(5-((3-flu0rophen0xy)methyl)isoxazol-3 -y1)pyrr01idiny1)—2-(1— hydroxy-3 ,3 ,5 ,5-tetramethy1cyclohexy1)ethanone, or (S)- l -((3 -(l—(2,2-difluoro(1-hydroxy-3 ,3 ,5,5 —tetramethylcyclohexyl)acetyl)pyrrolidin-2— yl)isoxazolyl)methyl)pyridin—4(l H)-one, or a pharmaceutically acceptable salt thereof; (IX) A pharmaceutical comprising as an active ingredient the compound or pharmaceutically acceptable salt thereof according to any one of (I) to (VIII) and (I’); and (X) An agent for preventing or treating alopecia which comprises as an active ingredient the compound or pharmaceutically acceptable salt thereof according to any one of (I) to (VIII) and (I’).
ADVANTAGEOUS EFFECTS OF ION The compounds of the present invention and pharmaceutically acceptable salts thereof bound to FKBP12 and inhibited its peptidyl-prolyl isomerase (rotamase) activity. In addition, the compounds and pharmaceutically acceptable salts f had such high solubility that they showed profiles preferred for external use. Moreover, the compounds and pharmaceutically acceptable salts thereof showed an outstanding hair-development stimulating action.
The compounds of the present invention and pharmaceutically acceptable salts thereof do not markedly suppress the protein phosphatase calcineurin, so they have no serious immunosuppressing ty. Consequently, it is expected that preparations containing the compounds or pharmaceutically acceptable salts thereof exhibit high safety e when used as agents for preventing or treating alopecia.
BRIEF DESCRIPTION OF DRAWINGS shows the hair development stimulating effect of nd I in shaven mouse . shows the hair pment stimulating effect of Compound 40 in shaven mouse models. shows the anagen induction stimulating effect of Compounds 40, 52, 59, 61, 63, and 64 in shaven mouse models.
PTION OF EMBODIMENTS The ing are the definitions of several important terms as used in this specification.
The term “halogen atom” means a e atom, a chlorine atom, a bromine atom, or an iodine atom.
The term “C1_6 alkyl group” means a straight or branched alkyl group having 1 to 6 carbon atoms and examples include a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, an isopropyl group, an isobutyl group, a tert—butyl group, a sec-butyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a 1,2- dimethylpropyl group, etc.
The term “C1-6 alkoxy group” means a straight or branched alkoxy group having 1 to 6 carbon atoms and examples include a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentyloxy group, a hexyloxy group, an isopropoxy group, an oxy group, a tert-butoxy group, a sec—butoxy group, an isopentyloxy group, a neopentyloxy group, a tert-pentyloxy group, a 1,2-dimethylpropoxy group, etc.
The term “aryl group” means an aromatic carbocyclic group, which is monocyclic to tetracyclic, and that is composed of 6 to 18 carbon atoms, and es include a phenyl group, a naphthyl group, an anthryl group, a phenanthryl group, a tetracenyl group, a pyrenyl group, etc.
The term “heteroaryl group” means a monocyclic or fused cyclic aromatic heterocyclic group and examples include a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a nyl group, a thienyl group, a yl group, a thiazolyl group, an azolyl group, a pyrazolyl group, an imidazolyl group, a furyl group, an oxazolyl group, an isoxazolyl group, an oxadiazolyl group, a 1,3,4-thiadiazolyl group, a 1,2,3—triazolyl group, a triazolyl group, a tetrazolyl group, a quinolyl group, an isoquinolyl group, a naphthyridinyl group, a quinazolinyl group, a benzofilranyl group, a benzothienyl group, an indolyl group, a benzoxazolyl group, a benZoisoxazolyl group, a lH—indazolyl group, a 2H— indazolyl group, a benzimidazolyl group, a benzoxadiazolyl group, a benzothiadiazolyl group, an indolizinyl group, a benzofurazanyl group, a thienopyridyl group, a -10.. pyrazolopyridyl group, an imidazopyridyl group, an imidazopyrazinyl group, a pyrazolopyrimidinyl group, a triazolopyrimidinyl group, a thienothienyl group, an imidazothiazolyl group, etc.
The term “mono-CM alkylamino group” means an amino group substituted by a single C1-6 alkyl group as defined above and examples include a amino group, an mino group, a propylamino group, abutylamino group, a pentylamino group, a hexylamino group, an isopropylamino group, an isobutylamino group, a tert-butylamino group, a sec-butylamino group, an isopentylamino group, a neopentylamino group, a tert- pentylamino group, a 1,2—dimethylpropylamino group, etc.
The term _6 alkylamino group” means an amino group substituted by two respectively independent C1-6 alkyl groups as defined above and examples include a dimethylamino group, a diethylamino group, a dipropylamino group, a dibutylamino group, a dipentylamino group, a dihexylamino group, a diisopropylamino group, a diisobutylamino group, a di—tert-butylamino group, a di-sec-butylamino group, a di—isopentylamino group, a di-neopentylamino group, a t-pentylamino group, a di-l,2-dimethylpropylamino group, an ethylmethylamino group, an isopropylmethylamino group, an isobutylisopropylamino group, etc.
The term “CM alkylsulfonyloxy group” means a yloxy group substituted by the CM, alkyl group defined above and examples include a methylsulfonyloxy group, an ethanesulfonyloxy group, a n—propylsulfonyloxy group, an isopropylsulfonyloxy group, a n- butylsulfonyloxy group, a 2-methyl—n—butylsulfonyloxy group, a tert-butylsulfonyloxy group, a n—pentylsulfonyloxy group, a n-hexylsulfonyloxy group, etc.
In the compounds of the t invention, X is preferably a bond, -CH20-, -CH2—, —(CH2)2-, —(CH2)3-, -O-, -CH2-NHC(=O)-, -CH2-NHC(=O)-CH2-, or -CH2-NHS(=O)2-; and X is more preferably -CH20-; in addition, preferably, R1 is formula (2); and ring A is either one of the rings ented by the following formula (5) <5») ; and R2 is a phenyl group or a pyridyl group (said phenyl group or l group may be substituted by 1-3 y groups.) The term “alopecia” means a condition in which some or all hairs have shedded or disappeared or have changed to thinner and shorter hairs. Alopecia manifests itself in various types which include, but are not particularly limited to, male pattern alopecia, heic alopecia, alopecia senilis, alopecia areata, alopecia medicamentosa due, for example, to the administration of cancer control drugs, scarring alopecia, and postpartum alopecia which manifests itself after delivery. Alopecia often results from a disrupted hair cycle and is triggered by a shortened anagen phase due, for example, to the arrest of cell proliferation.
The term “hair cycle” refers to the growth cycle of hairs and represents a period consisting of three , (1) the anagen phase (the period during which the hair follicle repeats division to cause active growth of the hair; the anagen phase lasts from two to six years for the hairs on the scalp); (2) the catagen phase (the period during which the hair growth is lessened and the follicle shrinks; the catagen phase lasts from one to two weeks for scalp hair); and (3) the telogen phase (the period during which the follicle is completely degenerated and remains dormant; the n phase lasts from three to four months for scalp hair.) Usually, '80 to 90 percent of the hairs are in the anagen phase and less than one percent are in the catagen phase, with the remainder in the telogen phase. Alopecia involves abnormalities in the hair cycle and, particularly in male n alopecia, the duration of the anagen phase is shortened and the hair makes a transition to the catagen/telogen phase before it grows to a thicker terminal hair, so the percentage of hairs in the telogen phase increases and the al hair s to a fine vellus. [003 5] The term “agents for preventing or treating alopecia” according to the present invention refers to drugs that have either one of the ing actions: (1) inducing a transition from the telogen phase to the anagen phase (i.e., inducing hair development); (2) stimulating hair growth; (3) extending the anagen phase; and (4) inhibiting, delaying or reducing the shedding of. hairs; drugs having more than one action are desired. [003 6] The term “pharmaceutically acceptable salts” means salts that are acceptable from a pharmaceutical viewpoint. es include: salts with acids such as acetic acid, propionic acid, butyric acid, formic acid, trifluoroacetic acid, maleic acid, ic acid, citric acid, c acid, succinic acid, ethylsuccinic acid, malonic acid, lactobionic acid, gluconic acid, glucoheptonic acid, c acid, methansulfonic acid, ethanesulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid (tosylic acid), laurylsulfuric acid, malic acid, aspartic acid, glutamic acid, adipic acid, cysteine, N- acetylcysteine, hydrochloric acid, romic acid, phosphoric acid, sulfuric acid, hydroiodic acid, nicotinic acid, oxalic acid, picric acid, thiocyanic acid, noic acid, acrylic acid polymer, and carboxyvinyl polymer; salts with inorganic bases such as lithium salts, sodium salts, potassium salts, and calcium salts; and salts with organic amines (e.g., morpholine and piperidine) and amino acids. [003 7] The compounds of the present invention and pharmaceutically acceptable salts thereof can occur in various solvated forms. They may also be ted to hydrates from the viewpoint of applicability as pharmaceuticals. [003 8] The compounds (1) of the present ion or pharmaceutically acceptable salts thereofmay be used as they are or, alternatively, they may be ated into preparations together with pharmaceutically able carriers by per se known techniques.
Pharmaceutically able carriers are various organic or inorganic materials commonly used as pharmaceutical necessities depending on whether they are used in solid ations or liquid preparations: examples for use in the former case include excipients (e.g., lactose, saccharose, D-mannitol, starch, corn starch, crystalline cellulose, light silicic anhydride, etc.), lubricants (e.g., magnesium stearate, calcium stearate, talc, colloidal silica, etc), binders (e.g., crystalline cellulose, saccharose, D—mannitol, dextrin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, cellulose, carboxymethylcellulose sodium, etc.), disintegrants (e.g., starch, carboxymethylcellulose, ymethylcellulose calcium, croscarmelose sodium, carboxymethyl starch sodium, low-substitution ypropyl cellulose, etc.); examples for use in liquid preparations include solvents (e.g., water for injections, alcohols, ene glycol, macrogol, sesame oil, corn oil, etc.), solvent ers (e.g., polyethylene glycols, propylene glycol, itol, benzyl benzoate, ethanol, minomethane, cholesterol, anolamine, sodium carbonate, sodium citrate, etc.), suspending agents (e.g., surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium de, benzethonium chloride, glyceryl monostearate, etc. or hydrophilic polymers such as nyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, etc.), ic agents (e.g., e, D—sorbitol, sodium chloride, glycerin, D-mannitol, etc.), buffering agents (e.g., phosphates, acetates, carbonates, citrates, etc.), and soothing agents (e.g., benzyl alcohol, etc.) In the course of pharmaceutical formulation procedure, various additives may be used depending on the need, as exemplified by preservatives (e.g., ybenzoate esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.), antioxidants (e.g., sulfites, ic acid, etc.), coloring agents, sweetening agents, adsorbents, wetting agents, etc.
The compounds of the present invention or pharmaceutically acceptable salts thereof may be administered orally or non-orally (e.g., intravenously, topically, rectally, etc.) Dosage forms of their administration may be exemplified by tablets (including sugar-coated tablets and film-coated tablets), powders, es, dusts, troches, capsules (including soft capsules), liquids, injections (e.g., subcutaneous, intravenous, intramuscular, intraperitoneal, etc.), external preparations (e.g., for nasal administration, transdermal application, ointments, creams, etc.), suppositories (e.g., rectal, vaginal, etc.), slow-release preparations (e.g., slow- release microcapsules, etc.), pellets, drops, etc.; each of these dosage forms may be manufactured by common pharmaceutical formulation techniques (e.g., the methods described in the 15th Japanese Pharmacopoeia.) External ations are a preferred dosage form due, for example, to the capability of being ly administered to the affected area, ease of administration, and a lower risk of causing ic side s. The compounds can also be used as oral ations since they exert no immunosuppressing action and the risk for systemic side effects is low.
The thus produced agents ofthe present invention for preventing or treating alopecia are administered in doses that can be appropriately adjusted depending on such factors as the , age, and sex of the patient. Specifically, if the agents are used as an external preparation, the compounds ofthe present invention are incorporated at concentrations of 0.0001% to 20% and the resulting preparation can be stered once to several times a day. Upon administration, the external preparation is applied to hairs in amounts ranging from about 0.00001 to about 4 mg/cmz, preferably from about 0.01 to about 1 mg/cmz.
If the agents are to be used as an oral preparation, they may be administered once to several times a day, with the compounds ofthe t ion being contained in daily amounts of 1 to 1000 mg/kg per adult.
Moreover, the compounds of the present invention can be used in combination with other active ingredients for agents that are effective in preventing or treating alopecia. Drugs that can be combined include but are not d to minoxidil and finasteride. The compounds can also be combined with such drugs as other hair growth stimulants/hair restorers, vasodilators, anti-androgens, cyclosporine derivatives, anti-microbials, anti- inflammatories, thyroid hormone derivatives, prostaglandin agents or antagonists, ids, and triterpenes. The compounds and the other active ingredients for agents that are effective in preventing or treating alopecia may be used as separate preparations or, alternatively, they may be used as a single combined drug.
While the method for producing the compounds of the present invention is described below, it is by no means limited to the following examples. Starting nds used to produce the compounds can be readily prepared by known methods or per se known methods. Production methods A to E are described below, with focus being placed on the construction of ring A. As for the addition of the organic e -R1, the following description assumes a method of ucing the same at the last stage but it may be introduced before constructing ring A or at an intermediate stage. on or transformation of the organic residue -X—R2 may also be carried out at any suitable stage. Any reactive functional group that occurs in respective steps may be protected and deprotected as appropriate.
Production method A Among the compounds ented by the general formula (1), those in which ring A is represented by the following formula: (Y; represents an oxygen atom, NMe, or NH) may be produced by, for example, the following method.
(Scheme A) (Step A- 1) (Step A-Z) [HZ—w.“We (Step A-3) fix,R2 H2N\ Y1 N e/NxOMe (3'3) \ _...__ (3‘5) P X,R2—.. (am.4) (3'1) (a-z) (Step A-4)- (Step A-LS) w—fi M N / \Y‘ (38) I: I /R Xe"RZ X R2 Rl x 2 (3-7) (a—9) {a6) (where R1, R2 and X have the same meanings as defined above; P represents an amino protecting group (e.g., a t-butoxycarbonyl group, a benzyloxycarbonyl group, etc.); Y1 represents an oxygen atom, NMe or NH; and L ents a hydroxy group or a leaving group (e.g., chlorine, bromine, iodine, etc.)) (1) Step A-l To obtain a compound represented by formula (a-2), a compound represented by formula (a-l) is reacted with methoxymethylamine h commonly practiced acylation.
For example, the carboxylic acid compound represented by formula (a—l) is reacted with thionyl chloride, chloride, etc. so that it is converted to the corresponding acid halide or, alternatively, the compound of formula (a-l) is reacted with ethyl chloroforrnate, yl chloroformate, etc. so that it is converted to the corresponding mixed acid anhydride; the resulting product is then reacted with methoxymethylamine either in a solvent or with no solvent used, optionally in the presence of a base. The compound represented by formula (a- 2) can also be obtained by reacting the compound (a—l) with methoxymethylamine using a condensing agent such as ohexylcarbodiimide or l-ethy1-3 -(3- dimethylaminopropyl)carbodiimide. The t may be a halogen-based solvent such as methylene chloride or chloroform, an ether—based solvent such as tetrahydrofuran or dioxane, an aromatic hydrocarbon—based solvent such as e or xylene, an c polar t such as N,N—dimethyformamide, or mixtures of these solvents. The base may be an organic base such as pyridine or triethylamine, or an inorganic base such as sodium hydroxide or sodium hydrogencarbonate. (2) Step A—2 To obtain a compound represented by formula (a-4), a compound represented by formula (a-3) may be reacted With an organometallic t such as MeLi, n-BuLi or EtMgBr in a solvent to generate an acetylide, which is then reacted with the compound of formula (a—2). The t may be an based solvent such as tetrahydrofuran or dioxane, an aliphatic hydrocarbon solvent such as hexane or pentane, or mixtures of these solvents. (3) Step A-3 To obtain a compound represented by formula (a-6), the compound of formula (a—4) is reacted with a nd represented by formula (a—S) or a salt thereof either in a solvent or with no solvent used, optionally in the presence of an acid or a base. The solvent may be an l such as methanol or ethanol, an ether-based solvent such as tetrahydrofuran or dioxane, an aprotic polar solvent such as N,N—dimethyformamide, water, or es ofthese solvents. The acid may be an inorganic acid such as hydrochloric acid or sulfuric acid, or an organic acid such as acetic acid or p-toluenesulfonic acid. The base may be an organic base such as pyridine or triethylamine, or an inorganic base such as AcONa, NaOMe, NazSO4, or K2CO3. (4) Step A-4 To obtain a compound ented by formula (a-7), the amino protecting group in the compound of formula (a-6) is d for deprotection. If the protecting group is a t- butoxycarbonyl group, deprotection may be effected by carrying out reaction with an acid such as trifluoroacetic acid or hloric acid; if the protectging group is a benzyloxycarbonyl group, ection may be effected either by enation in the presence of a catalyst such as ium—carbon or platinum oxide or by reaction with an acid such as HBr-AcOH. If other protecting groups are to be removed, methods commonly practiced to remove the amino protecting group of interest may be implemented. (5) Step A-5 To obtain a compound represented by formula (a—9), a compound represented by formula (a—8) (where L is an OH group) is treated by the same method as described in Step A—l so that it is converted to an acid halide and then reacted with the compound of formula (a-7), or it may be directly reacted with the compound of formula (a-7) in the presence of a condensing agent. Alternatively, a compound represented by formula (a-9) may be obtained by reacting a compound of formula (a—8) (where L is a leaving group) with the nd of formula (a—7) in a solvent, optionally in the presence of a base.
Production method B Among the compounds represented by the general formula (1), those in which ring A is represented by the following formula: -an<g: \‘fq may be produced by, for example, the following method. e 8) (Step B- 1) (Step B-2) ‘ M(Step B--3) (b1’ (b~2) (b3) (Step B4) (Step B-S) WfiNH% —, Ma \ I X’RZ XflR? x—a-Rz (ID-5) (b-S) (15.7) (Step B-6) R14, N (6-7) \ i "mmii_5. i R1 x-v-Rz (5-8) (Where R1, R2 and X have the same gs as defined above; P represents an amino protecting group (e.g., a t-butoxycarbonyl group, a benzyloxycarbonyl group, etc); L represents a hydroxy group or a leaving group (e.g., chlorine, bromine, iodine, etc.)) (1) Step B—l To obtain a compound represented by formula (b-2), a compound represented by formula (b—l) is reacted with CBr4 and PPh3 in a halogen-based solvent such as methylene chloride or chloroform by the method described in l of Medicinal Chemistry, 1990, vol. 33, page 3190 or a modified version ofthe method. (2) Step B-2 To obtain a compound represented by formula (b-3), the nd of formula(b-2) is reacted with a base in a solvent. The base may be MeLi, n-BuLi, sec-BuLi, Pr)2, or the like. The solvent may be an ether-based solvent such as tetrahydrofuran or dioxane, an aliphatic hydrocarbon solvent such as hexane tane, or mixtures of these solvents. (3) Step B-3 To obtain a compound ented by formula (b-5), the compound (b-3) may be reacted with an organometallic t such as MeLi, n-BuLi or EtMgBr in a solvent to generate an acetylide, which is then reacted with a compound represented by (b—4). The t may be an ether-based solvent such as tetrahydrofuran or dioxane, an aliphatic hydrocarbon solvent such as hexane or pentane, or mixtures of these solvents. To obtain a compound represented by formula (b-S), an acetylide corresponding to the compound of a (b—3) generated in situ by the reaction described in Step B-2 may be reacted with the compound of formula (b-4). (4) Step B—4 To obtain a compound represented by formula (b-6), the compound of forrnuola (b— ) is reacted with hydroxylamine or a salt thereof either in a solvent or with no solvent used, optionally in the ce of an acid or a base. The solvent may be an alcohol such as methanol or l, an ether-based solvent such as tetrahydrofilran or dioxane, an aprotic polar solvent such as N,N-dimethyformamide, water, or mixtures ofthese solvents. The acid may be an inorganic acid such as hydrochloric acid or sulfuric acid, or an organic acid such as acetic acid or p-toluenesulfonic acid. The base may be an c base such as pyridine or triethylamine, or an inorganic base such as AcONa, NaOMe, NaZSO4, or K2C03. (5) Step B-5 A compound represented by formula (b-7) is obtained from the compound of formula (b—6) by the same method as described in Step A-4. (6) Step 3-6 A compound represented by formula (b-8) is obtained from the compound of formula (b-7) by the same method as described in Step A-S.
Production method C Among the nds represented by the l formula (1), those in which ring A is represented by the following formula: (where Y2 represents an oxygen atom or a sulfur atom) may be produced by, for example, the following method.
(Scheme C) (Step C—l) (Step C-2) (Step C-3) W H H 2 CHN N \NHz ‘3 X’Rz M \NH \ OH .........__, “i 0 42-32.... ’2 ..___._..,...
P 0 P P O XIRZ (a4) (c4) (c—3) 0% \NN (Step c 4) 0% \N- N (Step c 5)- ii RTL Y J42 fi Y ”/4 N 2 [N P (3-8) X”R2 X’R2 Y24 - i521 X’Rz (c4) (c-S) (c-6) (where R1, R2 and X have the same meanings as defined above; P represents an amino protecting group (such as a t-butoxycarbonyl group, a benzyloxycarbonyl group, etc); Y2 represents an oxygen atom or a sulfur atom; L represents a hydroxy group or a leavting group (e.g., chlorine, bromine, iodine, etc.)) (1) Step C-l A compound represented by formula (0-1) is obtained from the nd of formula (a—l) and hydrazine by the commonly practiced acylation which is described in Step A- 1 . (2) Step C-2 A compound represented by formula (c-3) is obtained from the compounds of formula (c-l) and (0-2) by the commonly practiced acylation which is described in Step A-l. (3) Step C—3 Among the compounds represented by formula (0-4), a nd Where Y2 is an oxygen atom is obtained by subjecting the compound of formula (c-3) to cyclodehydration in a solvent using Burgess reagent or CBr4, PPh3, imidazole, etc. The solvent may be a halogen-bassed solvent such as methylene chloride or chloroform, or an aromatic hydrocarbon solvent such as toluene or xylene.
Among the compounds represented by a (0-4), a compound Where Y2 is a sulfur atom is obtained by reacting the compound of a (c—3) with Lawesson’s reagent or the like in a t. The solvent may be a halogen-bassed solvent such as methylene chloride or chloroform, or an aromatic hydrocarbon solvent such as toluene or xylene. (4) Step C—4 A nd represented by formula (c—5) is obtained from the compound of formula (0-4) by the same method as described in Step A—4. (5) Step C—S A compound represented by formula (0—6) is obtained from the compound of formula (c—5) by the same method as described in Step A-S.
Production method D Among the nds represented by the general formula (1), those in which ring A is represented by the ing formula: N3. .. . fl/ 1 (where Y3 represents a hydrogen atom or a Me group) may be produced by, for example, the following method. -22_ e D) (Step D-l) o * H Wk /Y23 . Nx. /v3 » N . N N ‘ H H E) 0H m E 0. (3-1) (CM) . (cl-2) (Step D-3) (Step 134) Rq-L -——-—-» (a8) (6-5) (Where R1, R2 and X have the same meanings as defined above; P represents an amino protecting group (such as a t-butoxycarbonyl group, a benzyloxycarbonyl group, etc.); Y3 represents a hydrogen atom or a Me group; L represents a hydroxy group or a leaving group (e.g., ne, bromine, iodine, etc.)) (1) Step D-l A compound represented by formula (d-2) can be obtained from the compound of formula (a—l) by reacting it with a hydrazine compound of formula (d-l) by the commonly practiced acylation Which is described in Step A-l; alternatively, the compound of formula (a- 1) may be reacted with a protected form of hydrazine corresponding to the hydrazine compound of formula (d-l) and then deprotected. (2) Step D-2 A compound represented by formula (d-4) is obtained from the compound of formula (d-2) and a cyano compound of formula (d—3) by means of heating in a t, optionally in the presence of an acid or a base. The solvent may be an alcohol such as ol or butanol, or an ether-based solvent such as dioxane or ylether. The acid may be an organic acid such as acetic acid. The base may be an inorganic base such as NaOMe or K2CO3. The reaction may be med at a temperature ranging from the solvent’s reflux temperature to 220°C under atmospheric or superatmospheric pressure or under microwave irradiation. (3) Step c-3 A compound represented by formula (d-5) is obtained from the compound of formula (d-4) by the same method as described in Step A-4. (4) Step C-4 A compound ented by formula (d-6) is obtained from the compound of formula (d-5) by the same method as described in Step A-S.
Production method E Among the nds ented by the general formula (1), those in which ring A is represented by the following formula: may be produced by, for example, the following method.
(Scheme E) (Step E-l) (Step E-2) HO\N 0%o A (H \No (H \No 5i HZN XWR: / OH ii 0 hi \N/IA p AL... P H2N X..R2 '—”' X..R2 ‘5‘” (e4) (e-S) (Step 13-3) [Mm (Step E-4) Wm ‘ N N a M 'l M ——'————.» X’Rz ——_* P waz (64) (9'5) (where R1, R2 and X have the same meanings as defined above; P represents an amino protecting group (such as a t-butoxycarbonyl group, a benzyloxycarbonyl group, etc.); L represents a y group or a leaving group (e.g., ne, bromine, iodine, etc.» (1) Step E-l A compound represented by formula (e-2) can be obtained from the compound of formula (a-l) by reacting it with a compound of formula (e-l) by the commonly practiced _24_ acylation which is bed in Step A-l. (2) Step E-2 A compound represented by formula (e-3) is obtained by subjecting the compound of formula (6-2) to dehydration in a solvent, optionally in the presence of an acid or a base.
The solvent may be an ether-based solvent such as dioxane or an aromatic hydrocarbon t such as toluene or xylene. The acid may be an organic acid such as p-toluenesulfonic acid. The base may be an organic base such as ne or triethylamine or an ammonium salt such as n-Bu4NF. The on may be performed at a temperature ranging from room temperature to the solvent’s reflux temperature. (3) Step E-3 A compound represented by formula (e-4) is obtained from the compound of formula (e-3) by the same method as described in Step A-4. (4) Step E-4 A compound represented by formula (e-5) is obtained from the compound of formula (e-4) by the same method as described in Step A—5.
Production method F Among the nds ented by the general formula (1), those in which ring A is represented by the following formula: (where Y4 represents an oxygen atom or a sulfur atom) may be produced by, for example, the following method.
(Scheme F) (Step F-l) (Step F-Z) Q{Z i2;% 7a Q ~ N? *y l o 0/ 4 P P (f1) X’R? XAR (a4) (f 2) (f-s) (Step F3) (Step F4) [N13Ql ‘xe’R'é xw—Rz (f4) ,(f~5), (where R1, R2 and X have the same gs as defined above; P represents an amino protecting group (such as a t-butoxycarbonyl group a benzyloxycarbonyl group, etc.); Y4 ents an oxygen atom or a sulfur atom; L represents a hydroxy group or a leaving group (e.g., chlorine, bromine, iodine, etc.)) (1) Step F-l A compound represented by formula (f-2) can be obtained from the compound of formula (a-l) by reacting it with a compound of formula (f-l) by the commonly practiced acylation which is described in Step A-l. (2) Step F-2 Among the compounds ented by formula (f-3), a compound where Y4 is an oxygen atom is obtained by subjecting the compound of formula (f-2) to cyclodehydration in a solvent using Burgess t or CBr4, PPh3, imidazole, etc. The solvent may be a halogen-bassed solvent such as methylene de or chloroform, or an aromatic hydrocarbon solvent such as toluene or xylene.
Among the compounds represented by a (f-3), a compound where Y4 is a sulfur atom is obtained by reacting the compound of formula (f-2) with Lawesson’s reagent or the like in a solvent. The solvent may be a halogen-bassed solvent such as methylene chloride or chloroform, or an aromatic hydrocarbon t such as toluene or xylene. (3) Step 13—3 —26- A nd represented by formula (f-4) is obtained from the compound of formula (f—3) by the same method as described in Step A—4. (4) Step F—4 A compound represented by a (f—S) is obtained from the compound of formula (f—4) by the same method as described in Step A-5.
EXAMPLES On the following pages, the present invention is described in greater detail by means of working examples and test examples. It should be noted that the compounds of the present invention are by no means limited to those described in the following working examples.
Unless otherwise noted: M. S. GEL 0-A (product I CHEMICAL INDUSTRY, LTD.) was used as a carrier in silica gel chromatography; Chromatorex NH-DM1020 (product of FUJI SILYSIA CHEMICAL LTD.) was used as a carrier in NH—form silica gel chromatograpyy; Silica Gel 60N (product of Kanto al Co., Inc.) or KP-Si120 um silica gel (product of Biotage) was used as a carrier in neutral silica gel chromatography.
The NMR spectra were those ofproton NMR; tetramethylsilane was used as an internal reference, with 8 values being indicated in ppm.
MS measurements were med using LC/MS-2010EV (equipped with dual ESI/APCI source).
Reverse-phae preparative HPLC was performed using GILSON preparative HPLC system. The following column and solvents were used for preparative purposes.
Column: Waters, SunFire Prep C18, OBD 5.0 um, 30 x 50mm Column Solvents: CH3CN (0.1% CF3COOH), H20 (0.1% CF3COOH) The iations used in the g examples have following meanings.
AcOEt: ethyl acetate APCI: atmospheric pressure chemical ionization Boc: t-butoxycarbonyl Brine: saturated aqueous sodium chloride DBU: diazabicycloundecene DPPA: diphenylphosphoryl azide Et3N: triethylamine EtZO: diethylether ESI: electrospray ionization HOBt: 1-hydroxybenzotriazole MsCl: methanesulfonyl chloride NMP: N—methyl—pyrrolidone Pd-C: palladium on carbon PPh3: triphenylphosphine PTLC: ative thin-layer chromatography THF: tetrahydrofuran WSC: l-ethyl(3-dimethylaminopropyl)carbodiimide hydrochloride Burgess reagent: methyl N-(triethylammonimnsulfonyl)carbamate Lawesson’s reagent: 2,4-bis(4-methoxypheny1)-1 -dithiadiphosphetane—2,4-disulfide s: singlet br.s.: broad singlet d: t dd: double doublet m: multiplet Example 1 difluoro-2—( 1-hydroxy-3 ,3 ,5,5—tetramethylcyclohexyl )ethanone g Compound 1 1 Example 1 -( 1) [0 1 0 1 ] S 3 4-Dimethox henox meth l rrolidin 1 isoxazole In an argon here, n—BuLi (147 mL as 2.76 N hexane on) was added to a solution of 1,2-dimethoxy(propynyloxy)benzene (81.85 g) in THF (1000 mL) at -60°C to -70°C over 55 minutes and after stirring at the same temperature for 30 minutes, a solution of (S)-t-butyl 2-(methoxy(methyl)carbamoy1)pyrrolidine-1—carboxy1ate (100.00g) in THF (600 mL) was added dropwise and temperature was raised to room temperature over 2 hours, followed by stirring at 25°C for 30 minutes. The reaction mixture was added to a saturated aqueous solution ofNH4Cl (3 L), ice water ( 2 L), hexane (1 L) and AcOEt (1 L); the organic layer was separated, washed with brine (5 L), water (2 L), and brine (1 L) successively, dried (MgSO4), filtered and concentrated to give a brown oil (161.24 g), which was dissolved in EtOH (1000 mL); to the solution, ylamine hydrochloride (53.79 g) was added and after heating under reflux for 13 hours, the mixture was stirred at room temperatuare for 13 hours. After reheating under reflux for 6 hours, the reaction e was trated to give a brown oil, to which HCl (1000 mL as 4.0 N AcOEt solution) was added and the mixture was stirred at room temperataure for 64 hours. To the reaction mixture, water (2 L) was added and after separating the c layer, NaOH (230 g) was added to the aqueous layer under cooling with ice; after extraction with CHC13 (2 L), the organic layer was dried (Na2804), filtered and concentrated to givd a crude product, which was further purified by neutral silica gel chromatography CHClg) to give the titled compound (49.98 g, brown oil.) 1H NMR (200MHz, CHLOROFORM-d) 8 6.78 (d, J = 8.8 Hz, 1 H), 6.57 (d, J = 3.1 Hz, _29_ 1H), 6.45 (dd, J = 3.1, 8.8 Hz, 1 H), 6.31 (3,1 H), 5.07 (s, 2 H), 4.38 - 4.24 (m, 1 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.22 - 2.92 (m, 2 H), 2.33 - 1.72 (m, 4 H) e 1-(2) difluoro 1-h drox -3 3 5 ameth lc clohex lethanone Com oundl To a solution of 2,2-difluoro(1-hydroxy-3,3,5,5—tetramethy1cyclohexyl)acetate (87.83 g) and Et3N (122 mL) in THF (2000 mL), ethyl chloroformate (30.8 mL) was added at room temperature and the mixture was stirred for 30 minutes. To the reaction mixture, a THF (500 mL) solution of the compound (89.00 g) obtained in Example 1-(1) was added dropwise at room temperature over an hour and the mixture was stirred at room ature for 20 hours. The reaction e was concentrated and AcOEt (2 L) and a saturated aqueous solution ofNH4C1 (2 L) were added; after filtereing the insoluble matter, the organic layer was separated and washed with saturated aqueous sodium bicarbonate (2 L), dried (MgSO4), filtered and concentrated to give a crude product (165.0 g). A similar method was applied using 2,2-difluoro(1-hydroxy-3,3,5,5-tetramethy1cyclohexyl)acetate (34.64 g) and (S)((3,4-dimethoxyphenoxy)methyl)(pyrrolidin-2—yl)isoxazole (35.10 g) to give a crude product (60.10 g), which was combined with the first crude product and further purified by silica gel chromatography (AcOEt/hexane) and NH—form silica gel chromatography (AcOEt/hexane); the purified product was recrystallized (EtzO/pentane) to give the titled compound (134.30 g, colorless powder.) 1H NMR (600MHz, CHLOROFORM-d) 8 6.78 (d, J = 8.7 Hz, 1 H), 6.57 (d, J = 2.8 Hz, 1 H), 6.44 (dd, J = 2.8, 8.7 Hz, 1 H), 6.26 [6.18] (s, l H), 5.43-5.39 [5.60 - 5.55] (m, 1 H), .11 - 5.00 (m, 2 H), 4.23 — 4.13 (m, 1 H), 3.99 — 3.71 (m, 2 H), 3.86 (s, 3 H), 3.84 (s, 3 H), 2.34 - 0.78 (m, 22 H) m.p. 99.0-101.0°C Example2 -2 2-Difluoro—2- l—h drox -3 3 5 5-tetrameth 1c clohex l -1— 2- 5- lox meth lisoxazol l rrolidin—l- lethanone Com ound 4O Example 2—(1) [01 07] >821.
S -t-But 12- h drox imino meth 1 rrolidine-l-carbox late To a solution of (S)—t-butylformylpyrrolidinecarboxylate (40.94 g) in ne (411 mL), hydroxylamine monohydrochloride (28.56 g) was added at 0°C and the e was stirred at room temperature for 17 hours. The reaction mixture was added to a mixture of AcOE (1.5 L) and hydrochloric acid (2 L, 3.0 N). The organic layer was separated, washed with saturated aqueous sodium bicarbonate (1 L), dried (MgSO4), filtered and trated to give the titled compound (39.78 g, colorless solid.) ESI+ 237(M+Na)+ Example 2-(2) [O 1 09] ylate To a DMF (60 mL) solution of the compound (8.57 g) obtained in Example 2-(1), NCS (5.341 g) was added in small portions at 0°C and the mixture was stirred at room ature for an hour. The on mixture was cooled to 0°C and after adding a solution of 3-(prop—2-yn-l-yloxy)pyridine (2.663 g) in THF (5 mL) and a solution of Et3N (5.6 mL) in THF (15 mL), the resulting mixture was stirred at room temperature for 14 hours. The reaction mixture was added to ted aqueous sodium bicarbonate (200 mL), followed by extraction with AcOEt (200 mL). The resulting organic layer was washed with brine (200 mL), dried (MgSO4), filtered and trated to give a crude product, which was further purified by neutral silica gel chromatography (AcOEt/hexane) to give the titled compound (3.81 g, pale yellow solid.) 1H NMR (200 MHz, CHLOROFORM-d) 8 8.42-8.26 (m, 2 H), 7.30-7.20 (m, 2 H), 6.39-6.19 (m, 1 H), 5.18 (br s, 2 H), 5.10-4.86 (m, 1 H), 3.65-3.35 (m, 2 H), 2.44—1.83 (m, 4 H), 1.59— 1.14 (m, 9 H) Example 2-(3) ' ' rrolidin l isoxazole To an AcOEt (20 mL) solution of the nd (3.81 g) obtained in Example 2-2, HCl (40 mL, 4.0 N AcOEt solution) was added and the mixture was stirred at room temperature for 40 hours. After concentrating the reaction mixture, saturated aqueous _32_ sodium bicarbonate (200 mL) and sodium chloride were added, ed by extraction with CHC13 (200 mL X 2). The resulting organic layer was dried (Na2S04), filtered and concentrated to give the titled compound (2.614 g, brown oil.) 1H NMR (200 MHz, CHLOROFORM-d) 8 8.42-8.35 (m, 1 H), .25 (m, 1 H), .19 (m, 2 H), 6.35 (s, 1 H), 5.17 (s, 2 H), 4.39-4.26 (m, 1 H), 3.20-2.93 (m, 2 H), 2.30—1.70 (m, 4 H) Example 2-(4) -2 2-Diflu0ro l-h drox -3 3 5 5-tetrameth lc clohex l —1— 2— 5- lox meth lisoxazol l rrolidin—l- lethanone Com ound 40 To a solution of 2,2-difluoro(1 -hydroxy-3,3,5,5-tetramethylcyclohexyl)acetic acid (3.192 g) and Et3N (4.44 mL) in THF (100 mL), ethyl chloroformate (1.12 mL) was added at room temperature and the mixture was stirred for an hour. To the reaction mixture, a THF (50 mL) solution of the compound (2.607 g) obtained in Example 2-(3) was added dropwise at room temperature and the mixture was stirred at room temperature for 64 hours.
To the reaction mixture, saturated s sodium bicarbonate (200 mL) was added and the organic layer ted with AcOEt (200 mL) was washed with brine (200 mL), dried (MgSO4), d and concentrated to give a crude product, which was further purified by NH-form silica gel chromatography (AcOEt/hexane); the resulting comound was recrystallized (Eth/pentane) to give the titled compound (2.969 g, colorless powder.) 1H NMR (600 MHz, CHLOROFORM-d) 8 8.41-8.34 (m, 1 H), 8.32 - 8.25 (m, 1 H), 7.28 - 7.20 (m, 2 H), 6.29 [6.20] (s, 1 H), 5.41-5.37 [5.58 - 5.55] (m, 1 H), 5.17-5.12 (m, 2 H), 4.20 - 4.13 (m, 1 H), 3.90 - 3.70 (m, 2 H), 2.33 - 0.82 (m, 22 H) mp. 102.0-104.0°C Example 3 -3 3 5 5-tetrarneth lc clohex ,1 2— 5- 3 4 5- trimethox henox meth lisoxaol 1 rrolidin-l- lethanone Com ound 21 Example 3—(1) In an argon atmosphere, n-BuLi (10.3 mL, 2.64 N hexane solution) was added dropwise to a solution of t-butyldiphenyl(prop—2-yn-l-yloxy)silane (8.576 g) in THF (200 mL) at -78°C over 10 minutes, and after stirring at room temperature for 50 minutes, the reaction e was added dropwise to a solution of (S)-t-buty1 2- (methoxy(methyl)carbamoyl)pyrrolidinecarboxy1ate (5.01 g) in THF (200 mL) through a cannula and temperature was raised to room temperature over an hour. The reaction mixture was added to a saturated aqueous solution ofNH4C1 (500 mL) and, after extraction with AcOEt, the c layer was dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by neutral silica gel chromatography (AcOEt/hexane) to give the titled compound (5.36 g, colorless oil.) CI Dual Na)+ Example 3-(2) [01 19] S tert-But ldi hen lsil 1 ox meth l rrolidin—2- l isoxazole To an EtOH (10 mL) solution of the compound (492 mg) obtained in Example 3-(1), hydroxylamine hydrochloride (139 mg) was added and the mixture was heated under reflux for 17 hours. To the reaction mixture, saturated aqueous sodium bicarbonate (50 m1) Was added and the organic layer ted with AcOEt was dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by neutral silica gel chromatography ( AcOEtfiMeOH/CHCI3) to give the titled compound (163 mg, brown oil.) ESI/APCI Dual 407(M+H)+ Example 3-(3) difluoro 1-h drox -3 3 5 5-tetrameth lc clohex 1 ne The procedure of Example 1-(2) was repeated, except that the compound obtained in Examle 1-(1) was replaced by the compound (150 mg) ed in Example 3-(2); this gave the titled compound (133 mg, colorless amorphous.) ESI/APCI Dual 639(M+H)+ Example 3-(4) [01 23] S -2 2-Difluoro l-h drox -3 3 5 ameth 1c clohex 1 2- 5— h drox meth 1isoxazol 1 olidin—l- lethanone Com ound 18 To a THF (20 mL) solution of the nd (1.784 g) obtained in Example 3-(3), n-Bu4NF (3.4 mL, 1.0 M THF solution) was added and the mixture was stirred at room temperature for 20 minutes. To the reaction e, a saturated aqueous solutioln ofNH4C1 was added and the organic layer extracted with AcOEt was dried (MgSO4), filtered and concentrated to give a crude product, which was further purified with neutral silica gel chromatography (AcOEt/hexane) to give the titled compound (1.010 g, ess solid.) ESI/APCI Dual 426(M+Na)+ Example 3-(5) (S H31 1-(2,2-Difluoro—2—§ 1-hydroxy-3,3,5,5- ethylcyclohexyl zacetyl zpyrrolidin-Z-yl )isoxazol-S-yl )methyl methanesulfonate To an AcOEt (3 mL) solution ofthe compound (45 mg) obtained in Example 3-(4) and Et3N (31 uL), MsCl (13 uL) was added at 0°C and after stirring the mixture for 30 minutes, MsCl (13 uL) was added and the mixtdure was stirred at 0°C for 30 minutes, followed by on of Et3N (31 uL) and stirring at 0°C for 2.5 hours. The reaction mixture was added to water (50 mL) and the organic layer extracted with AcOEt (50 mL) was dried -36— (MgSO4), filtered and concentrated to give the titled compound (58 mg, colorless oil.) ESI/APCI Dual 501(M+Na)+ e 3-(6) -2 2-Difluoro l-h drox —3 3 5 5-tetrameth lc clohex 1 2— 5- 3 4 5— hox henox meth lisoxazol—3— l rrolidin-l— lethanone Com ound 21 To a DMF(1.0 mL) solution of the compound (20.8 mg) obtained in Example 3-(5) and 3,4,5-trimethoxyphenol (16.0 mg), K2C03 (24.0 mg) was added and the mixture was stirred at room temperature for 30 minutes, then at 50°C for 2 hours. The on mixture was added to water (20 mL) and the organic layer extracted with AcOEt (20 mL X 2) was dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by PTLC rm) to give the titled compound (20.5 mg, colorless amorphous.) 1H NMR (600MHz, CHLOROFORM-d) 5 6.30 - 6.16 (m, 3 H), 5.61 - 5.35 (m, 1 H), 5.14 - .02 (m, 2 H), 4.25 - 4.12 (m, 1 H), 3.84 (s, 6 H), 3.80 (s, 3 H), 3.94 - 3.68 (m, 2 H), 2.36 - 0.85 (m, 22 H) ESI/APCI Dual 589(M+Na)+ Example 4 S -N- 3- 1- 2 2-Difluoro 1—h drox -3 3 5 5- tetrameth lc clohex lacet 1 rrolidin—Z- lisoxazol—S— lmeth lbenzamide Com ound Example 4-(1) h drox —3 3 5 ameth lc clohex lethanone To a mixture of toluene (20 mL) with the compound (657 mg) obtained in Example 3-(4), DBU (368 uL) and DPPA (530 uL) were added and the resulting mixture was stirred at room temperature for 20 hours. To the reaction mixture, water (50 mL) was added and the organic layer extracted with AcOEt (50 mL) was washed with brine (50 mL), dried ), filtered and concentrated to give a crude product, which was further purified by neutral silica gel chromatography /hexane) to give the titled compound (645 mg, colorless amorphous.) ESI/APCI Dual 426(M+H) Example 4-(2) S -l— 2- 5- Aminometh l isoxazol-3— l -2 2-difluoro 1-h drox - 3 ,3 5 5-tetramethylcyclohexyl one (Compound 42 2 , , To a THF(20 mL) solution of the compound (632 mg) obtained in Example 4-(1), PPh3 (779 mg) and water (1.0 mL) were added and the mixture was heated under reflux for 3 hours. The reaction mixture was concentrated and after adding water (50 mL), extraction with AcOEt (50 mL X 2), drying (NaZSO4), filtering and concentrating were performed to give a crude product, which was further purified by NH-form silica gel chromatography (AcOEt/hexane) and neutral silica gel chromatography (MeOH/CHClg) to give the titled nd (463 mg, colorless amorphous.) ESI/APCI Dual 400(M+H) t Example 4-(3) [01 3 5] S -N- 3- 1- 2 2-Difluoro—2- l-h drox -3 3 5 5- eth 1c clohex lacet l olidin-2— lisoxazol-S- lmeth mide Com ound The compound (40 mg) obtained in Example 4—(2) was dissolved in CHC13 (3 ml) and after adding benzoyl de (17 uL) and Eth (43 uL), the mixture was stirred at room ature for 19 hours. To the reaction mixture, CHC13 (20 m1) and 5% KHSO4 (20 ml) were added to separate the organic layer. The resulting organic layer was washed with saturated aqueous sodium bicarbonate (20 ml) and brine (20 ml), dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by silica gel chromatography (AcOEt/hexane) to give the titled compound (43 mg, colorless amorphous.) ESI/APCI Dual 504(M+H) t Example 5 -39_ S -N- 3- l- 2 2-Difluoro l—h drox -3 3 5 5- tetrameth lo clohex lacet l rrolidin—Z- lisoxazol-S- lmeth lbenzenesulfonamide (Compound 45] The titled compound was obtained by repeating the procedure of Example 4—(3), except that benzoyl chloride was ed by benzenesulfonyl chloride.
ESI/APCI Dual 540(M+H) t Example 6 -l- 2- 5- Dimcth lamino meth 1 isoxazol l ' ' —2 2-difluoro-2— l-h drox -3 3 5 S-tetrameth lc clohcx lethanone Com ound 46 The compound (160 mg) obtained in Example 3-(5) was ved in MeCN and after adding a THF solution of dimethyllamine (2 M, 250 uL), the mixture was stirred at room temperature for 3 hours. To the reaction mixture, AcOEt 3(50 ml) and a saturated aqueous on ofNaC03 (50 ml) were added to separate the organic layer. The ing organic layer was washed with brine (50 ml), dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by silica gel tography (AcOEt/hexane) to give the titled compound (83 mg, colorless amorphous.) ESI+ 428(M+H) Example 7 S 1- C clohex lmeth l sulfon l rrolidin—2- 1 3 4- dimethox henox meth lisoxazole Com ound 43 To a THF (10 mL) solution of the compound (913 mg) obtained in Example 1-(1), a THF (5.0 mL) solution of Eth (555 uL) and cyclohexylmethanesulfonyl chloride (393 mg) was added and the mixture was stirred at room temperature for 3.5 days. To the reaction mixture, a saturated aqueous solution ofNH4C1 (50 mL) was added and the c layer obtained by tion with AcOEt (50 mL X 2) was washed with brine (50 mL), dried (MgSO4), filtered and trated to give a crude product, which was further purified by neutral silica gel chromatography /hexane) and NH—form silica gel chromatography (AcOEt/hexane) to give the titled compound (202 mg, ess amorphous.) ESI/APCI Dual 465(M+H) +, 487(M+Na)+ Example 8 S -l- 2- 5- 3 4-Dimethox henox methil -1 3 4-oxadiazol l olidin-l 2 2-difluoro l-h drox -3 3 5 5-tetrameth lc clohex l ethanone Com ound 2 Example 8-(1) S -t-But l2— 2- 2- 3 4-dimethox henox acet lh drazinecarbon l rrolidine-l- carboxylate To a solution of (S)-t-butyl 2-(hydrazinecarbonyl)pyrrolidine—l—carb0xylate (50.0 g) and 2-(3,4-dimeth0xyphenoxy)acetic acid (47.8 g) in chloroform (1000 ml), HOBt (35.3 g) and WSC hydrochloride (50.0 g) were added and the mixture was stirred at room temperature for 4 hours. After distilling off the solvent under d pressure, water was added, ed by extraction with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium bicarbonate and brine and dried over MgSO4 before it was filtered.
The solvent was distilled off under d pressure to give a crude form of the titled compound (61.0 g). 1H NMR (200 MHz, CHLOROFORM-d) 5 ppm 8.79 (br. s., 1 H), 6.78 (d, J=8.79 Hz, 1 H), 6.58 (d, J=2.64 Hz, 1 H), 6.40 (dd, J=8.79, 3.08 Hz, 1 H), 4.57 (s, 2 H), 4.47 - 4.32 (m, 1 H), 3.87 (s, 3 H), 3.84 (s, 3 H), 3.52 - 3.32 (m, 2 H), 2.48 - 2.30 (m, 1 H), 2.03- 1.87 (m, 3 H), 1.54- 1.43 (m, 9 H) Example 8-(2) S -t-But 12- 5- 3 thox henox meth 1 —1 3 4-oxadiazol carboxylate >Us “to To a toluene (700 ml) solution of the compound (61.0 g) obtained in Example 8-(1), Burgess reagent (45.0 g) was added and the mixture was stirred at 120°C for 4 hours. After adding water to the reaction mixture, the organic layer extracted with AcOEt was dried (Na2S04), filtered and had the solvent distilled off under reduced pressure; the ing residue was purified by silica gel chromatography (AcOEt) to give the titled compound (42.0 g). 1H NMR (600 MHz, CHLOROFORM-d) 8 ppm 6.77 (d, J=8.71 Hz, 1 H), 6.62 - 6.57 (m, l H), 6.51 (dd, J=8.94, 2.98 Hz, 1 H), 5.21 - 5.13 (m, 2 H), 5.07 - 5.01 (m, 1H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.66 - 3.38 (m, 2 H), 2.42 - 2.22 (m, 1 H), 2.20 - 2.06 (m, 2 H), 1.99 (m, 1 H), 1.26 — 1.49 (m, 9 H) Example 8-(3) To an AcOEt (200 ml) on of the compound (42.0 g) obtained in Example 8—(2), 4N HCl-AcOEt solution (200 ml) was added and the mixture was stirred at room temperatuare for 4 hours. The solvent was distilled off under d pressure to give a crude form of the titled compound (35.0 g). 1H NMR (200 MHZ, DMSO'd6) 8 ppm 6.88 (d, J=8.79 Hz, 1 H), 6.70 (d, J=3.08 Hz, 1 H), 6.64 - 6.55 (m, l H), 5.38 (s, 2 H), 5.13 - 5.00 (m, 1 H), 3.75 (s, 3 H), 3.70 (s, 3 H), 3.34 - 3.23 (m, 2 H), 2.44 - 1.90 (m, 4 H) Example 8-(4) S -1— 2- 5- 3 4-Dimethox henox meth l -1 3 4-oxadiazol l difluorog 1 -hydroxy-3 ,3 ,5 ,5—tetramethylcyclohexyl )ethanone ( Compound 2 ) [01 5 1 ] _43_ The procedure of Example 1—(2) was repeated, except that the compound obtained in Example l-(l) was ed by the compound (35.0 g) obtained in Example 8—(3); the resulting crude t was r purified by silica gel column chromatography (AcOEt/hexane) and thereafter recrystallized with AcOEt-pentane to give the titled compound (39.0 g) as a colorless solid. 1H NMR (600 MHz, CHLOROFORM-d) 6 ppm 6.80 — 6.77 (m, 1 H), 6.62 - 6.60 (m, 1 H), 6.50 (dd, J=8.71, 2.75 Hz, 1H), 5.50 — 5.46[5.71-5.67](m,1H), 5.21 — 5.15 (m, 2 H), 4.41 - 4.34 (In, 1 H), 3.97 (s, 1 H), 3.86 (s, 3 H), 3.84 (s, 3 H), 3.80 — 3.72 (m, 1 H), 2.37 - 0.79 (m, 22 H) Example 9 S -2 2-Difluoro-2— l-h drox -3 3 5 5-tetrameth lc clohex l —1'- 2- 5- henox meth 1-1 3 4-oxadiazol 1 rrolidin-l- lethanone Com ound 29 Example 9-(1) >LLOoK,02 [S H-Butyl 2-[211te1‘t— but ldi hen lsil 10x acet lh drazinecarbon 1 rrolidine-l-carbox late _44_ A mixture of CHCl3 (100 mL) with (S)-t-butyl 2-(hydrazinecarbonyl)pyrrolidine carboxylate (4.791 g), 2-((t-butyldiphenylsily1)oxy)acetic acid (6.28 g), WSC ' HCl (4.371 g) and HOBt ' H20 (3.081 g) was stirred at room temperature for 15 hours. To the reaction mixture, a saturated s solution ofNH4C1 (500 mL) was added, followed by extraction with AcOEt (500 mL). The organic layer was washed successively with saturated aqueous sodium bicarbonate (500 mL) and brine (500 mL), dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by silica gel chromatography /hexane) to give the titled compound (6.42 g, colorless amorphous.) ESI/APCI Dual 548(M+Na) + Example 9-(2) S -t-But 12- 5- tert-but ldi hen lsil lox meth 1-1 3 4—oxadiazol-2— yl [pmolidinecarboxylate To a toluene (112 mL) solution ofthe nd (5.87 g) obtained in Example 9-(1), ' Burgess reagent (5.322 g) was added and the mixtdure was heated under reflux for 2.5 hours.
The reaction mixture was trated to give a crude t, which was further purified by silica gel chromatography (AcOEt/hexane) to give the titled compound (4.151 g, colorless ous.) ESI/APCI Dual 508(M+H) +, 530(M+Na) + Example 9-(3) [01 5 9] rrolidin—2- l -1 3 4-oxadiazole To a THF (3.8 mL) solution of the compound (3.832 g) ed in Example 9-(2), H3PO4 (6.1 mL, 85% aqueous solution) was added and the mixtdre was stirred at room temperature for an hour. To the reaction mixture, THF (50 mL) was added and the resulting mixture was added to NaOH (150 mL, 1.0 N aqueous solution) and ice (50 g), followed by tion with CHC13 (300 mL). The organic layer was dried (NaZSO4), filtered and concentrated to give a crude product, which was further purified by NH-form silica gel chromatography (MeOl-I/CHClg) to give the titled compound (1.261 g, colorless oil.) ESI/APCI Dual 408(M+H) + Example 9-(4) text-But ldi hen lsil 1 ox meth 1—13 iazol-2— l 1— l -2 2-difluoro l-h drox -3 3 5 S-tetrameth 1c clohex l ethanone The procedure of Example 1-(2) was repeated, except that the nd obtained in Example l-(l) was replaced by the compound (1.186 g) obtained in Example 9-(3); this gave the titled nd (1.287 g, colorless amorphous.) ESI/APCI Dual 640(M+H) J“, 662(M+Na) Example 9-(5) [01 63] -46— F/Ko O’K/OH S -2 oro l-h drox —3 3 5 5-tetrameth 1c clohex 1 —1- 2- 5- h drox meth -1 3 4-oxadiazol 1 rrolidin-l- lethanone Com ound 22 The procedure of Example 3-(4) was repeated, except that the compound obtained in Example 3-(3) was ed by the compound (1.378 g) obtained in Example 9-(4); this gave the titled compound (750 mg, colorless solid.) ESI/APCI Dual 402(M+H) t, 424(M+Na)+ Example 9-(6) / '\:N , =O\ yo :0/8\ S - 5— 1— 2 2—Difluoro l-h drox -3 3 5 5- tetrameth 1c clohex l acet l olidin—2- 1-1 3 4-oxadiazol lmeth lmethanesulfonate gCompound 23) The procedure of Example 3—(5) was repeated, except that the compound obtained in Example 3-(4) was replaced by the compound (340 mg) obtained in Example 9-(5); the resulting crude product was recrystallized (AcOEt/hexane) to give the titled compound (7349 mg, colorless .) ESI/APCI Dual 480(M+H) t, Na)+ Example 9-(7) [Ol 67] S -2 2—Difluoro l-h drox -3 3 5 ameth 1c clohex l -l- 2- 5— henox meth 1-1 3 4-oxadiazol l rrolidin—l- 1 ne Com ound 29 To a DMF(1.0 mL) solution of the compound (32.5 mg) obtained in Example 9-(6) and phenol (13 mg), K2C03 (37 mg) was added and the mixtdure was stirred at 50°C for 3.5 hours. The reaction mixture was added to water (20 mL) and the organic layer extracted with AcOEt (20 mL X 2) was dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by silica gel chromatography (AcOEt/hexane) to give the titled compound (31.6 mg, colorless amorphous.) ESI/APCI Dual 478(M+H) +, 500(M+Na) + Example 10 S -N- 5— 1- 2 2—Difluor0—2— l—h drox -3 3 5 5- tetrameth lc clohex lacet l rrolidin—Z— 1-1 3 iazol—2- lmeth lbenzamide (Compound 3 8) The procedure of Example 4 was repeated, except that the compound obtained in e 3-(4) was replaced by the compound obtained in Example 9—(6); this gave the titled ESI/APCI Dual 505(M+H) +, 527(M+Na)+ Example 11 difluoro-Z- 1-h drox -3 3 5 S-tetrameth lc clohex lethanone Com ound 39 The procedure of Example 6 was repeated, except that the compound obtained in e 3-(5) was replaced by the compound obtained in e 9-(6); this gave the titled compound.
ESI/APCI Dual H) t, 451(M+Na)+ Example 12 S -1— 2— 3- 3 4-Dimethox henox meth 1 -1 2 4-oxadiazol l 2 2-difluoro 1-h drox —3 3 5 5-tetrameth 1c clohex 1 ne Com ound 3 Example 12-(1) L”N_ 2- 3 4-Dimethox henox -N'—h drox acetoimidamide To a solution of 2-(3,4-dimethoxyphenoxy)acetonitrile (3.8 g) in MeOH—H20 (1:1), hydroxyamine hydrochloride was added and the mixture was stirred at 100°C for 3 hours.
After distilling off the solvent under reduced pressure, the residue was recovered by filtration and washed with water and hexane to give a crude form of the titled compound (4.9 g).
ESI/APCI Dual H) +, 249(M+Na) + Example 12-(2) -t-But 12- 3- 3 4—dimethox henox meth 1-1 2 4—oxadiazol l oxylate To a CHC13 (20ml) solution of the compound (1.0 g) ed in Example 12-(1) and (S)(tert—butoxycarbonyl)pyrrolidine—2-carboxylic acid (1.0 g), WSC ' HCl ( 1.0 g) was added and the e was stirred at room temperature for 4 hours. Water was added, followed by extraction with CHCl3. After distilling off the solvent under reduced pressure, the residue was dissolved in toluene (20 ml), followed by refluxing for 2 hours. The solvent was distilled off under reduced pressure and the residue was purified by silica gel chromatography (AcOEt/hexane) to give the titled compound (190 mg).
ESI/APCI Dual 424(M+H) +, 446(M+Na) + Example 12-(3) S 2— 3- 3 4—Dimethox henox meth l -1 2 iazol l 2 2-difluoro 1—h drox —3 3 5 5-tetrameth 1c clohex l ethanone Com ound 3 The procedures of Example 2-(3) and Example 2-(4) were repeated, except that the compound obtained in Example 2-(2) was replaced by the compound obtained in Example ; this gave the titled compound.
ESI/APCI Dual 53 8(M+H) t, 560(M+Na) + Example 13 1- l -2 2-difluoro—2- l-h drox -3 3 5 ameth 1c clohex l ne Com ound 9 Example 13-(1) S -t-But 1 2- 4— 3 4-dimethox henox but no 1 rrolidine-l—carbox late To a THF (50 mL) solution of 1,2-dimethoxy-4—(propyn—yloxy)benzene (2.118 g), n-BuLi (4.0 mL, 2.64 N hexane solution) was added dropwise at -78°C and the resulting mixture was stirred at the same temperature for 30 minutes; the reaction mixture was then added dropwise to a solution of (S)—t-buty1 2- (methoxy(methyl)carbamoyl)pyrrolidine—1—carboxy1ate (2.578 g) in THF (100 mL) at -78°C and, after stirring at the same temperature for an hour, temperature was raised to room temperature over an hour. The reaction mixture was added to a saturated aqueous solution of NH4C1 (300 mL) to separate the organic layer, which was washed with a saturated aqueous solution ofNH4C1 (100 mL), dried (Na2SO4), filtered and trated to give a crude product, which was further purified by neutral silica gell tography (AcOEt/hexane) to give the titled compound (2.479 g, pale brown oil.) ESI/APCI Dual 412(M+Na) + Example 13-(2) [01 85] 7101.
S -t—But 12- 5- 3 4-dimethox henox meth l-l-meth l-lH- azol 1 rrolidine-l-carbox late To an EtOH (5.0 mL) solution of the compound (390 mg) obtained in Example 13- (1), methylhydrazine (106 uL) and sodium acetate (246 mg) were added and the mixture was heated under reflux for 20 hours. The on mixture was concentrated and a saturated aqueous solution ofNH4C1 (50 mL) was added to separate the organic layer, which was dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by neutral silica gel chromatography (AcOEt/hexane) to give the titled nd (378 mg, pale brown oil.) ESI/APCI Dual 418(M+H)+ Example 13-(3) To a CHC13 (1.0 mL) solution of the compound (365 mg) obtained in Example 13- (2), TFA (5.0 mL) was added at 0°C and the e was stirred at room temperature for 2 hours. After concentrating the reaction mixture, saturated s sodium bicarbonate (50 mL) was added and the organic layer extracted with CHC13 (50 mL X 2) was dried (Na2804), filtered and concentrated to give the titled compound (283 mg, pale brown oil.) ESI/APCI Dual 318(M+H)+ Example 13-(4) l— l -2 2-difluoro l—h drox -3 3 5 5-tetrameth 1c clohex l ethanone Com ound 9 The procedure of Example 1-(2) was repeated, except that the compound obtained in Example l-(l) was replaced by the compound (274 mg) obtained in Example ; the resulting crude product was further purified by silica gel chromatography (AcOEt/hexane) to give the titled d (129 mg, ess amorphous.) ESI/APCI Dual 550(M+H) +, 572(M+Na) t e 14 _, O difluoro l-h drox -3 3 5 S-tetrameth 1c clohex lethanone Com ound 10 Example 14-(1) _53_ 2- 3 4-Dimethox henox hox -N-meth lacetamide To a mixture of CHC13 (100 mL) with 2-(3,4-dimethoxyphenoxy)acetic acid (4.244 g), N,O-dimethylhydroxyamine hydrochloride (2.341 g), WSC ' HCl (4.984 g) and HOBt ' H20 (3.513 g), Et3N (3.62 mL) was added and the mixture was stirred at room temperature for 20 hours. The reaction mixture was concentrated, H20 (400 mL) was added, and the organic layer extracted with AcOEt (500 mL) was washed successively with saturated aqueous sodium dicarbonate (400 mL), water (400 mL) and brine (400 mL), dried (MgSO4), filtered and concentrated to give a crude product, which was furher d by silica gel chromatography (AcOEt) to give the titled compound (4.01 g, pale brown oil.) ESI/APCI Dual 256(M+H) + Example 14-(2) [01 95]. -3 -oxobut— 1 - n-l - 1 carboxylate To a THF (120 mL) solution of (S)-t-butyl 2-(2,2-dibromovinyl)pyrrolidine carboxylate (5.326 g), n—BuLi (11.6 mL, 2.64 N hexane solution) was added dropwise at —78°C and the e was stirred at the same temperature for an hour; thereafter, a THF (50 mL) solution of the compound (4.00 g) obtained in Example 14-(1) was added dropwise and temperature was raised to room temperature over an hour. The reaction mixture was added to a saturated aqueous on ofNH4C1 (400 mL) and the organic layer extracted with AcOEt (400 mL X 2) was dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by neutral silica gel chromatography (AcOEt/hexane) to give the titled compound (2.934 g, pale yellow oil.) ESI/APCI Dual 3 )' e 14-(3) [01 97] S -3— 3 4-Dimethox henox meth 1 rrolidin l isoxazole To an EtOH (10 mL) solution ofthe compound (390 mg) obtained in Example 14- (2), hydroxylamine hydrochloride (139 mg) was added and the mixture was heated under reflux for 20 hours. The on mixture was concentrated to give a brown oil, to which CHC13 (1.0 mL) and TFA (5.0 mL) were added, followed by stirring at room temperature for 21 hours. After concentrating the reaction mixture, saturated aqueous sodium bicarbonate (50 mL) was added and the organic layer extracted with CHCl3 (5OmL X 2) was dried (Na2S04), filtered and trated to give the titled compound (326 mg, brown oil) as a mixture with impurities.
ESI/APCI Dual 305(M+H) + Example 14-(4) difluoro-Z-g 1—hydroxy-3,3 ,5fi-tetramethylcyclohexyl )ethanone 1 Compound 1 0 1 The procedure of Example l-(2) was ed, except that the compound obtained in Example 1-(1) was replaced by the compound (321 mg) obtained in Example 14-(3); the resulting crude product was further d by neutral silica gel chromatography /hexane) and NH-form silia gel chromatography (AcOEt/hexane) to give the titled compound (142 mg, yellow amorphous.) CI Dual 537(M+H) t, 559(M+Na)+ Example 15 difluoro l-h drox -3 3 5 5-tetrameth lc clohex 1 ethanone Com ound 11 Example 15—(1) carboxylate To an EtOH (lOmL) solution ofthe compound (395 mg) obtained in Example 14- (2), hydrazine hydrate (63 uL) was added and the mixture was stirred at room temperature for minutes. The on mixture was concentrated, water (50 mL) was added, and the organic layer extracted with AcOEt (50 mL) was dried (MgSO4), filtered and concentrated to give the titled compound (466 mg, pale brown amorphous.) ESI/APCI Dual 404(M+H) +, 426(M+Na) + Example 15-(2) S 3 4-Dimethox henox meth 1 rrolidin 1 -1H- azole The procedure of Example 13-(3) was repeated, except that the compound obtained in Example 13-(2) was replaced by the compound (460 mg) obtained in Example 15—(1); this gave the titled compound (339 mg, pale brown oil.) ESI+ 304(M+H) Example 15—(3) difluoro-Z- l-h drox —3 3 5 ameth lc clohex l ne Com ound ll The procedure of Example 1-(2) was repeated, except that the compound obtained in Example l-(l) was ed by the compound (332 mg) obtained in Example 15—(2); the resulting crude product was filrther d by silica gel chromatography (AcOEt/hexane) to give the titled compound (463 mg, pale pink amorphous.) ESI/APCI Dual 536(M+H) i 558(M+Na) + Example 16 S -l— 2- 5- 3 4—Dimethox henox meth l —1 3 4-thiadiazol l 2 2-difluoro l-h drox -3 3 5 5-tetrameth lc clohex l ethanone Com ound 4 Example 16-(1) .‘N'\ . [02 12] l -carboxylate To a toluene (30 ml) solution of the compound (540 mg) obtained in Example 8-(1), Lawesson’s reagent (750 mg) was added and the e was stirred at 90°C for 6 hours.
After adding water, extraction was conducted with AcOEt. The solvent was distilled off under reduced pressure and the e was purified by silica gel chromatography (AcOEt/hexane) to give the titled nd (291 mg).
ESI/APCI Dual 422(M+H) +, 444(M+Na) Example 16-(2) [02 l 3] —58— S —1- 2- 5— 3 4-Dimethox henox meth l -1 3 4-thiadiazol l 2,2-difluoro-2—g l -hydroxy-3 ,3,5,5-tetramethylcyclohexyl )ethanone 1 nd 4 ) The procedures of e 2-(3) and Example 2-(4) were repeated, except that the compound obtained in Example 2-(2) was replaced by the compound obtained in Example 16-(1); this gave the titled compound.
ESI/APCI Dual 554(M+H) +, 576(M+Na) + Example 17 S 2— 5- 3 4—Dimethox henox meth 1 -4H-1 2 4-triazol l in—ll -2 2-diflu0ro—2— l-h drox -3 3 5 5-tetrameth lc clohex 1 ethanone Com ound 5 Example 17-(1) -t—But l 2- 5- 3 4-dimethox henox meth l —4H—1 2 zol l 1 -carboxy1ate To a n—butanol (10 ml) solution of 2-(3,4—dimethoxyphenoxy)acetonitrile (1.26 g) and (S)-t-butyl 2-(hydrazinecarbonyl)pyrrolidinecarboxylate (500 mg), K2CO3 (150 mg) was added. The resulting mixture was stirred at 160°C for an hour under microwave irradiation. After distilling off the solvent under reduced pressure, water was added, followed by extraction with ethyl acetate. After distilling off the solvent under d pressure, the residue was purified by silica gel chromatography and NH-form silica gel tography to give the titled compound (281 mg).
ESI/APCI Dual 405(M+H) Jr, 427(M+Na) + ’ Example 17-(2) S 2- 5- 3 4-Dimethox henox meth l -4H—1 2 4-triazol l rrolidin—l- l -2 2-difluoro 1-h drox -3 3 5 5-tetrameth lc clohex l ethanone Com ound 5 The procedures of Example 2-(3) and Example 2-(4) were ed, except that the compound obtained in Example 2-(2) was replaced by the compound obtained in e 17—(1); this gave the titled compound.
ESI/APCI Dual 537(M+H) +, 559(M+Na) + . Example 18‘ ii N = I.
S 2- 5- 3 4-Dimeth0x henox meth l meth l-lH—l 2 4-triazol l rrolidin-l- l —2 2-difluoro—2- l-h drox —3 3 5 5-tetrameth lc clohex l ethanone gCompound 8) -60— Example 18-(1) S -t-But l2— 5- 3 4-dimethox henox meth l -l—meth l-lH—l 2 4-triazol 1 rrolidine-l-carbox late Using (S)-t-butyl 2-(2-methylhydrazinecarbonyl)pyrrolidine-l-carboxy1ate in place of (S)—2-(hydrazinecarbonyl)pyrrolidine—1-carboxylate, the procedure of Example 17-(1) was repeated to give the titled compound.
ESI/APCI Dual 419(M+H) +, 441(M+Na) + Example 18-(2) 1Compound 8) The procedures of Example 2—(3) and Example 2-(4) were repeated, except that the compound ed in e 2-(2) was replaced by the compound obtained in Example ; this gave the titled compound.
ESI/APCI Dual 551(M+H) +, 573(M+Na) Example 19 difluoro-2— l-h drox -3 3 5 5-tetrameth lc clohex l ethanone Com ound 6 N»; -.
N/ N Example 19-(1) 1- 1H-Benzo d l 2 3 l-l- l 3 4—dimethox henox ethanone To a solution of 1H-benzo[d][l ,2,3]triazole (11.2 g) in CHC13 (120 m1), thionyl chloride (1.7 ml) was added and after stirring at room temperature for 30 minutes, 2-(3,4- oxyphenoxy)acetic acid (5.00 g) was added and the mixture was stirred at room ature for 1.5 hours. The precipitate was filtered off and the filtrate was washed with an aqueous solution of 2 N NaOH; thereafter, the organic layer was dried (MgSO4), d and concentrated to give the titled compound (8.06 g, colorless solid.) Example 19-(2) ch.\/,fl\\,,ov.c - ‘O/. o\\ 1- 3 4-Dimethox henox ro ro anone To a suspension of potassium tert-butoxide (3.38 g) in DMSO (60 ml), a solution of nitromethane (0.836 g) in DMSO (5 ml) was added at 10°C and the mixture was stirred at the same temperature for 30 minutes. A DMSO (65 ml) suspension of the compound (4.30 g) -62— obtained in e 19-(1) was added dropwise at 10°C and the mixture was stirred at the same temperature for an hour, then at room temperature for 3 hours. The reaction e was poured into water (250 m1), rendered acidic with 10% aqueous acetic acid, and subjected to extraction with AcOEt. The organic layer was washed with water, dried (MgSO4), d and concentrated to give a crude product, which was further purified by silica gel chromatography (AcOEt/hexane) and then recrystallized /hexane) to give the titled compound (0.808 g, pale yellow solid.) ESI/APCI Dual 254(M-H)' Example 19-(3) H22Nv.-\/U=\/OI l-Amino-3— 3 4-dimethox henox r0 anoneh drochloride To a MeOH (7 ml) solution of the compound (0.660 g) obtained in Example 19-(2), % Pd-C (0.330 g) and an aqueous solution of 1N HCl (14 ml) were added and the mixture was stirred at room temperature for 5 hours in a hydrogen gas atmosphere. The insoluble matter was filtered off and the filtrate was concentrated to give the titled compound (0.715 g, brown amorphous.) ESI/APCI Dual 226(M+H) + Example 19-(4) V. Ni >§oOoj\/O\.:o\o./ S -tert-But 12- 3- 3 thox henox oxo ro mo l rrolidine-l carboxylate To a THF (14 ml) solution of (S)(tert—butoxycarbonyl)pyrrolidine—Z-carboxylic acid (0.557 g) and Et3N (0.790 ml), ethyl chloroformate (0.295 g) was added over an ice bath, followed by stirring at the same temperature for 30 minutes. The reaction mixture was added at 0°C to a THF (7 ml) solution of the compound (0.701 g) obtained in Example 19-(3) and the mixture was stirred at room temperature for 17 hours. After adding water and performing extraction with AcOEt, the c layer was washed with saturated aqueous sodium chloride, dried (MgSO4), filtered and concentrated to give a crude product, which was r purified by silica gel chromatography (AcOEt/hexane) to give the titled compound (0.540 g, brown amorphous.) ESI/APCI Dual 445(M+Na) + Example 19-(5) S -t-But l2— 5— 3 4-dimethox henox meth loxazol l rrolidine—l- carboxylate To a toluene (10 ml) ofthe compound (0.250 g) obtained in Example 19-(4), Burgess reagent (0.281 g) was added and the e was stirred at 50°C for 1.5 hours. After reversion to room temperature, the reaction mixture was concentrated to give a crude product, which was further purified by silica gel chromatography (AcOEt/hexane) to give the titled compound (0.156 g, colorless oil.) CI Dual 405(M+H) + Example 19-(6) S 3 4-Dimethox henox meth 1 rrolidin loxazole To an AcOEt (1 ml) solution of the compound (0.146 g) ed in Example 19-(5), 4N HCl-AcOEt (0.5 ml) was added and the mixture was stirred at room temperature for 12 hours. After adding 4N HCl-AcOEt (0.5 ml) and stirring for 3 hours, 4N HCl-AcOEt (0.5 ml) was further added and stirring was continued for an hour. After adding an aqueous solution of 2N NaOH and performing extraction with AcOEt, the organic layer was washed with brine, dried (MgSO4), filtered and trated to give the titled compound (0.078 g, pale yellow solid.) . ESI/APCI Dual 305(M+H) + Example 19-(7) difluoro l-h drox -3 3 5 5-tetrameth 1c clohex lethanone Com ound 6 To a solution of 2,2—difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)acetic acid (0.075 g) and Et3N (0.038 ml) in THF (1 ml), ethyl chloroformate (0.028 g) was added over an ice bath, followed by stirring at the same temperature for an hour. To the reaction e, a on of (S)((3,4-dimethoxyphenoxy)methyl)(pyrrolidinyl)oxazo1e (0.075 g) in THF (1 ml) was added over an ice bath, followed by ng at room temperature for 15 hours. After adding water and performing extraction with AcOEt, the organic layer was washed with ted aqueous sodium chloride, dried (MgSO4), filtered and concentrated to give a crude product, which was further purified by silica gel chromatography (AcOEt/hexane) to give the titled compound g, colorless amorphous. ) ESI/APCI Dual 537(M+H) Example 20 _65_ S -l- 2- 5- 3 thox henox meth lthiazol l rrolidin-l- l difluoro-2— l-h drox -3 3 5 5-tetrameth lc clohex lethanone Com ound 7 Example 20-(1) carboxylate To a e (5 ml) solution of the compound (0.287 g) obtained in e 19-(4), Lawesson’s reagent (0.275 g) was added and the mixture was stirred at 110°C for an hour.
After reversion to room temperature, the reaction mixture was concentrated to give a crude product, which was further purified by silica gel chromatography (AcOEt/hexane) to give the titled compound (0.100 g, colorless amorphous.) ESI/APCI Dual 421 (M+H) + Example 20-(2) ‘ \ 'ENH S 3 4-Dimethox henox meth 1 olidin lthiazole The procedure of Example 19-(6) was repeated, except that the compound obtained in Example 19-(5) was replaced by the compound obtained in Example 20-(2); this gave the titled compound (0.063 g, colorless solid.) ESI/APCI Dual 321(M+H) + Example 20-(3) o-Z- l-h drox -3 3 5 5-tetrameth 1c clohex lethanone Com ound 7 The procedure of Example 19-(7) was repeated, except that the compound obtained in Example 19-(6) was replaced by the compound obtained in Example 20-(2); this gave the titled compound (0.077 g, colorless amorphous.) ESI/APCI Dual 575(M+Na) + e 21 NXW.
V .0 » /_. lox meth l isoxazol l rrolidin—l— 1 ethanone Com ound 53 A sealed tube was charged with a mixture prepared by adding e (2 ml) to nd 18 (30 mg), 4-bromopyridazine hydrobromide (22 mg), Pd(OAc)2 (2 mg), C32C03 (37 mg), and [l,l'—binaphthalen]yldi-tert-butylphosphine (3 mg) and the mixture was stirred at 100°C for 4 hours. After cooling the reaction mixture to room temperature, NH silica gel was added, followed by stirring for a while. After separating the silica gel by —67— filtration, the silica gel was washed with chloroform and the solvent was distilled off; the resulting residue was purified by reverse-phase preparativelHPLC to give the titled compound (6.0 mg, colorless oil.) 1H NMR (600MHz, CHLOROFORM-d) 8: 9.08 - 8.98 (m, 2 H), 7.02 - 6.96 (m, l H), 6.35 [6.26] (s, 1 H), 5.62 - 5.37 (m, l H), 5.22[5.24] (s, 2 H), 4.21 - 3.71 (m, 2 H), 2.38 - 0.82 (m, 22 H) Example 22 S -2 2-Diflu0ro-2— l-h drox —3 3 5 5-tetrameth lc clohex l 2— 5- yloxy [methyl [isoxazol-3 -yl [pvrrolidin- 1 —yl [ethanone 5 Compound 55 1 To a on of Compound 18 (40 mg) in DMF (10 ml), NaH (5.2 mg, >55% in minerai oil) was added and after stirring for 30 s, 2-bromopyrazine (23.8 mg) was added and the mixture was stirred at room temperature for 0.5 hour.
To the reaction mixture, DMSO (1.0 ml) was added and after filtering off the ble matter, the filtrate was purified by reverse-phase preparative HPLC to give the titled compound (6.7 mg, colorless oil.) 1H NMR z, CHLOROFORM-d) 5 8.34 — 8.29 (m, 1 H), 8.24 — 8.18 (m, 1 H), 8.13 - 8.08 (m, 1 H), 6.28 [6.19] (s, 1 H), 5.60 - 5.36 (m, 3 H), 4.24 - 4.13 (m, 1 H), 3.95 - 3.87 (m, 1 H), 3.82 - 3.69 (m, 1 H), 2.35 — 0.76 (m, 22 H) Example 23 (S)-2,2-Diflu0ro(1—hydroxy—3 ,3 ,5,5-tetramethylcyclohexyl)(2-(5 -((pyridin yloxy)methyl)isoxazolyl)pyrrolidin—1—yl)ethanone (Compound 54); and (S)-1—((3 -(1-(2,2-Difluoro-2—(1—hydroxy-3,3,5,5-tetramethylcyclohexyl)acety1)pyrrolidin yl)isoxazol-5—yl)methyl)pyridin—2(lH)-one (Compound 60) To a DMF (1.0 mL) solution of the compound (30 mg) ed in Example 3-(5) and n-Z-ol (12 mg), K2CO3 (35 mg) was added and the mixture was stirred at 50°C for an hour. To the reaction mixture, DMSO (1.0 ml) was added and after filtering offthe insoluble matter, the filtrate was purified by reverse-phase preparative HPLC to give Compound 54 (2.0 mg, colorless oil) and Compound 60 (16.0 mg, colorless oil.) S -2 oro 1-h drox yloxy )methyl )isoxazol-B -yl )pyrrolidinyl )ethanone 1 Compound 54 ) 1H NMR (600MHz, CHLOROFORM—d) 8 8.20 - 8.12 (In, 1 H), 7.66 - 7.57 (m, l H), 6.97 - 6.90 (m, 1 H), 6.85 — 6.78 (m, 1 H), 6.24 [6.15] (s, 1 H), 5.59 - 5.30 (m, 3 H), 4.25 - 4.14 (m, 1 H), 4.05 - 3.92 (m, 1 H), 3.81 — 3.69 (m, 1 H), 2.33 — 0.77 (m, 22 H) yl )isoxazol-S-yl )methyl n-Zg 1H )-one (Compound 60) 1H NMR (600MHz, CHLOROFORM-d) 8 7.42 = 9.1 Hz, - 7.31 (m, 2 H), 6.59 (d, J 1 H), 6.28 — 6.11 (m, 2 H), 5.56 — 5.07 (m, 3 H), 4.23 — 4.09 (m, 1 H), 3.98 - 3.83 (m, 1 H), 3.80 — 3.67 (m, 1 H), 2.35 — 0.72 (m, 22 H) Example 24' -2 oro l-h drox -3 3 5 5-tetrameth lc clohex 1 -l- 2- 5- ridin lox meth lisoxazol l rrolidin-l— lethanone h oride monoh drate 1Compound 67] To an AcOEt (50 ml) solution of Compound 40 (2.24g) obtained in Example 2, HCl (50ml, 4.0 N in AcOEt) was added and the mixture was stirred at room temperature for 15 hours, and aftrer adding pentane (140 ml), the e was stirred for 8 days. The residue obtained by concentrating the reaction mixture was tallized (MeOH/EtZO) to give the titled compound (2.23 g, colorless powder.) 1H NMR (600MHz, DMSO-ds) 8 = 8.65 - 8.52 (m, l H), 8.46 - 8.36 (m, l H), 7.97 - 7.84 (m, 1 H), 7.75 - 7.65 (In, 1 H), 6.61 [6.63] (s, 1 H), 5.79 - 3.01 (m, 7 H), 5.42 [5.44] (s, 2 H), 2.31 — 0.66 (m, 2.2 H) Anal. calcd for C25H33F2N304 ' HCl ' H20: C, 56.44; H, 6.82; N, 7.90; found C, 56.20; H, 6.66; N, 7.76.
The procedure of Example 3 was repeated to give the following compounds.
S -2 2-Difluoro 1-h drox —3 3 5 5-tetrameth lc clohex l 2— 5- 6- methoxypflidinyl [oxy [methyl [isoxazolyl [pyrrolidinyl [ethanone 1 Compound 41 ) 1H NMR (600MHz, CHLOROFORM-d) 8 7.91 - 7.82 (m, 1 H), 7.30 9 7.21 (In, 1 H), 6.74 - 6.66 (m, 1 H), 6.39 - 6.151(m, 1H), 5.60 - 5.33 (m, 1 H), 5.12 — 5.02 (m, 2 H), 3.89 (s, 3 H), 4.24 - 3.64 (m, 3 H), 2.35 - 0.84 (m, 22 H) g S [—2,2-Difluoro] oxy_-3,3,5,5-tetramethylcyclohexyl [] 2-] 5- (phenoxymethyl [isoxazolyl [pyrrolidin—l -yl [ethanone (Compound 52 ) _7()_ 1H NMR (600MHz, CHLOROFORM—d) 5 7.37 — 7.28 (m, 2 H), 7.05 - 6.92 (m, 3 H), 6.26 [6.18] (s, 1 H), 5.44 - 5.37 [5.60 - 5.54] (m, 1 H), 5.17 — 5.05 (m, 2 H), 4.41 — 3.54 (m, 3 H), 2.39 4 0.68 (m, 22 H) S -2 oro-2— 1-h drox -3 3 5 5-tetrameth lc clohex l —1- 2- 5— ‘rimidin-S- yloxy l )isoxazol-3 —yl )pflrolidinyl )ethanone 1 Compound 59 ] 1H NMR z, CHLOROFORM-d) 8 8.93 (s, 1 H), 8.49 (s, 2 H), 6.34 [6.25] (s, 1 H), .44 - 5.36[5.61- 5.56] (m, 1 H), 5.26 — 5.17 (m, 2 H), 4.21 — 4.11 (m, 1 H), 3.89 — 3.70 (m, 2 H), 2.38 - 0.77 (m, 22 H) S -2 2—Difluoro-l- 2- 5- 3-flu0ro henox ‘meth l isoxazol-3— l hydroxy—3 ,3 ,5,5-tetramethylcyclohexyl )ethanone 1 Compound 64 1 1H NMR (600MHz, CHLOROFORM-d) 5 7.30 — 7.21 (m, 1 H), 6.77 — 6.65 (m, 3 H), 6.27 [6.18] (s, 1 H), 5.44 — 5.38 [5.59 - 5.55] (m, 1 H), 5.15 — 5.05 (m, 2 H), 4.23 - 4.14 (m, 1 H), 3.93 - 3.87 (m, 1 H), 3.84 - 3.70 (m, 1 H), 2.35 - 0.78 (m, 22 H) S -2 2-Diflu0ro l-h drox -3 3 5 5-tetrameth lc clohex l 2- 5- toluyloxy )methyl )isoxazol-3 -yl )pyrrolidin-l -yl )ethanone ] Compound 65 ) 1H NMR (600MHz, CHLOROFORM-d) 6 7.13 — 7.08 (m, 2 H), 6.87 — 6.82 (m, 2 H), 6.25 [6.17] (s, 1 H), 5.44 — 5.37 [5.58 — 5.55] (m, 1 H), 5.13 — 5.04 (m, 2 H), 4.24 — 4.15 (m, 1 H), 3.98 - 3.91 (m, 1 H), 3.82 - 3.69 (m, 1 H), 2.30 (s, 3 H), 2.25 — 0.86 (m, 22 H) The procedure of Example 21 was repeated to give the following compound.
S -2 2-Difluor0 l-h drox -3 3 5 5-tetrameth 1c clohex l —1- 2- 5- ridin—4- yloxy l )isoxazol-3 -yl )py_rrolidinyl )ethanone [ Compound 57 ) 1H NMR (600MHz, CHLOROFORM-d) 6 8.49 (br. s., 2 H), 6.93 — 6.82 (m, 2 H), 6.30 [6.21] (s, 1 H), 5.46 — 5.35 [5.61— 5.55] (m, 1 H), 5.21 - 5.10 (m, 2 H), 4.24 - 4.08 (m, 1 H), 3.92 - 3.69 (m, 2 H), 2.40 - 0.75 (m, 22 H) The procedure of Example 22 was repeated to give the following compounds.
S —2 2-Difluoro l-h drox -3 3 5 ameth lc clohex l 2— 5- 3— 10X meth lisoxazol l rrolidin—l- lethanone Com ound 56 1H NMR (600MHz, CHLOROFORM-d) 8 8.93 — 8.86 (m, 1 H), 7.47 - 7.40 (m, 1 H), 7.10 — 7.02 (m, 1 H), 6.35 [6.25](s, 1 H), 5.70 — 5.60 (m, 2 H), 5.44 - 5.37 [5.60 — 5.56] (m, 1 H), 4.25 — 4.13 (m, 1 H), 3.99 — 3.87 (m, 1 H), 3.82 — 3.69 (m, 1 H), 2.35 — 0.77 (m, 22 H) S -2 oro 1-h drox -3 3 5 5-tetrameth lc clohex l 2- 5- yloxy [methyl )isoxazol-3 —yl )pyrrolidin— 1 -yl [ethanone ( Compound 5 8 2 1H NMR (600MHz, FORM-d) 6 8.59 - 8.52 (m, 2 H), 7.06 - 6.99 (m, l H), 6.30 [6.23] (s, l H), 5.63 - 5.35 (m, 3 H), 4.26 - 4.14 (m, 1 H), 4.02 - 3.91 (m, 1 H), 3.82 - 3.68 (m, l H), 2.38 — 0.75 (m, 22 H) The procedure of e 23 was repeated to give the following compounds. g S [-l-[ g 3-1 1—[2,2-Difluoro—2-] 1-hydroxy-3,3,5,5- tetramethylcyclohexyl [acetjgl [pyrrolidin-Z-yl [isoxazol-S-yl [methyl [pyrimidin-4] lH )-one [Compound 61) 1H NMR (600MHz, CHLOROFORM-d) 8 8.22 - 8.10 (m, 1 H), 7.36 - 7.30 (m, l H), 6.33 - 6.15 (m, 2H), 5.40 — 5.30 [5.60 — 5.54] (m, 1 H), 5.02 — 4.96 (m, 2 H), 4.17 — 4.06 (m, 1 H), 3.86 — 3.60 (m, 2 H), 2.36 — 0.77 (m, 22 H) S -3— 3— 1- 2 2-Difluoro 1—h drox —3 3 5 5-tetrameth lc clohex l acet l 511 [isoxazol-S—yl [methyl [pyrimidin—4] 3H )-one 1 Compound 62 1 1H NMR (600MHz, CHLOROFORM-d) 8 8.26 - 8.21 (m, l H), 7.95 - 7.87 (m, 1 H), 6.50 - 6.46 (m, 1H), 6.28 [6.21] (s, l H), 5.40 - 5.31 [5.57 - 5.50] (m, 1H), 5.21 - 5.11 (m, 2 H), 4.21 - 4.08 (In, 1 H), 3.91 - 3.68 (m, 2 H), 2.31 - 0.83 (m, 22 H) -2 oro l-h drox -3 3 5 5-tetrameth lc clohex l -l- 2—5- rimidin yloxy [methyl )isoxazolyl [pyrrolidin— l -yl )ethanone (Compound 63 [ 1H NMR z, CHLOROFORM-d) 6 8.81 (s, 1 H), 8.53 — 8.46 (m, 1 H), 6.85 — 6.79 (m, 1 H), 6.29 [6.20] (s, 1 H), 5.63 — 5.34 (m, 3 H), 4.24 — 4.13 (m, 1 H), 3.97 — 3.68 (m, 2 H), 2.38 — 0.77 (m, 22 H) 3- 1- 2 2-Difluoro 1-h drox -3 3 5 5-tetrameth 1c clohex 1 acet l rrolidin yl )isoxazol-S-yl [methy11pyridin—4] 1H [-one (Compound 66) 1H NMR (600MHz, CHLOROFORM—d) 6 7.36 - 7.30 (m, 2 H), 6.44 - 6.38 (m, 2 H), 6.16 [6.08] (s, 1 H), 5.61 — 5.31 (m, 1 H), 5.06 — 4.91 (m, 2 H), 4.22 — 4.07 (m, 1 H), 3.92 — 3.62 (m, 2 H), 2.38 — 0.77 (m, 22 H) Reference Example In e 2-(2), the following intermediate as generated in situ was used to perform cyclization; if desired, this intermediate may be isolated before the cyclization.
WN(“OHN >L,* Cl o S But 12- chloro h drox imino meth l rrolidine—l-carbox late To an AcOEt (270 ml) solution of the (S)—t-butyl 2- oxyimino)methyl)pyrrolidine-l-carboxylate (32.0 g) obtained in Example 2-(1), NMP (43 .1 ml) was added and after adding NCS (21.94 g) in three divided portions at 20- to 30- min intervals at 30 to 40°C, the resulting mixture was stirred at room temperature for 0.5 hour. The same reaction was carried out in a total of four runs using the same quantities. To the reaction mixture, water (400 ml) was added and the organic layer was separated. The separated organic layers were combined, washed with water (1.2 L X 2), dried (MgSO4), d and concentrated to give a crude product (pale yellow solid, 174 g), which was washed with AcOEt/hexane (AcOEt/hexane = 140 ml/840 ml) and dried to give the titled compound (109.3 g, colorless solid.) 1H NMR (600MHz, DMSO-d6) 8 11.77 - 11.62 (m, 1 H), 4.55 - 4.41 (m, 1 H), 3.58 - 3.20 (m, 2 H), 2.25 - 1.71 (m, 4 H), 1.39 [1.33] ( s., 9 H) ESI/APCI Dual 237(M+Na) + Using methods either the same as or similar to those described in Examples 1-24, the compounds fied in Table 1-1 to Table 1—11 were prepared. _73_ Table 1-1 Structural formula Preparation No. method Example ‘I (WW Example8 Example 12 (M+H)+ Compound 4 554 e16 Compound 5 537 119 Example17 Compound 6 537 500~1,000 Example19 Table 1-2 Compound 7 {M+Na)+ Compound 8 nd 9 Compound 10 (Magi)? Compound 11 Compound 12 Table 1-3 nd 13 Compound 14 Compound 15 Compound 16 As in Compound 17 Compound 18 Table 1-4 Compound 19 As in Example 9 As in Compound 20 276 Example 9 Compound 21 '.589 Example 3 Compound 22 402 1000~2000 Example 9 (5)_ nd 23 l ,000~ 2,000 Example 9-(6) As in Compound 24 .
Example9 ‘ Table 1-5 ExgrimpinTeB 351 glle8 As in Example 9 Table 1-6 531 AS in Compound 31 + Example9 Compound 32 522 As in (M+H)+ Example 9 517 As in Compound 33 ‘ (M+H)+ Example9 ‘ As in Compound 34 - 463 500~1.000 _ Example8 " Compound 35 476 AS in (M+H)+ Example1 Compound 36 480 As in 1.ooo~ 2,000 .
(WM Example9 Compound 37 40: 1.000~ 2,000 Example 10 ' Table 1-7 _30_ Table 1-8 540 Exam Ie 5 ..428 Example 6 giJIIe 4 Exgagl‘e 2 ‘ ExaAééTe 4 ExaArigre 4 ~81— Table 1-9 Exafigg 22 As in e 21 As in Example 22 _32_ Table 1—10 Compound 59 As in Example 3 50° Example 23 (M+Na)+ As in Example 23 As in Example 23 As in Example 23 As in As in Example 3 -83..
Table 1—11 . As in Com 0 nd 60 e 23 nd 67 (Test 1) Test for Measuring Immunophilin FKBP12 Rotamase Activity The rotamase (peptidylprolyl isomerase) inhibiting activity of each test compound was measured by a known method (Harding et al., Nature 341, 758-760, 1989; Holts et al., J.
Am. Chem. Soc. 115, 9925-993 8, 1993.) To be more specific, a plastic cuvette was charged with 35 mM HEPES (pH 7.8), 12 nM human recombinant FKBP12 (Sigma, F-5398), 0.4 mg/mL oc-chymotrypsin, and a tetst compound dissolved in DMSO at varying concentrations (DMSO’S final concentration was 0.1%.) uently, 24 mM of the substrate peptide, succinyl-Ala-Phe-Pro-Phe-paranitroanilide, as dissolved in trifluoroethanol containing 500 mM of LiCl was added to give a final concentration of 48 “M, whereupon reaction started. The reaction was carried out at 4°C and the change in absorbance at 390 nm accompanying the liberation of the paranitroaniline product was monitored. A calculateded initial rate minus the corresponding value in the absence of the enzyme was used as an index of se activity. The rotamase inhibiting activity of a test compound was expressed in relative values (%) with respect to the control value of rotamase ty in the absence of the compound, and the tration of the compound at which it was capable of inhibiting se activity by 50% was calculated as an ICso value from its concentration response curve.
The IC50 values of the respective test compounds are indicated in Table 1-1 to Table 1-1 1.
(Test 2) DissolutionTest To 5 g of 1,3—butylene glycol, 10 g of water was added and the mixture was d until homogeneity; thereafter, ethanol was added to make a total volume of 100 mL, whereby a base was prepared. An excess amount of a test compound was put into a test tube, the prepared base was added, and the mixture was stirred at 25°C for 7 days and passed through a membrane filter (0.45 mm); the resulting filtrate was diluted with acetonitrile and the concentration ofthe diluted solution was measured by HPLC to determine the solubility of the compound.
A comparative example (1—[2-((2$)[5-(3,4—dimethoxyphenoxy)methyl]-l,2,4— zol-3 —yl]pyrrolidin—1-yl)—l l -difluorooxoethyl]—3 ,3 ,5 ,5-tetramethylcyclohexanol, sed in WO2008/075735) had a solubility of 30.8 mg/mL whereas nd 1 had a solubility of 57.5 mg/mL.
(Test 3) Test for Measuring Hair Development Stimulating Effect in Shaven Mouse Model Method C57BL mice (female, ca. 7-wk old) were shaven on the back and the base prepared in Test 2 or a solution prepared by dissolving 5% (w/v) of Compound 1 in this base was administered by applying them to the shaven area in 200—pl, portions once daily starting 3 days after the g (each group consisting of 10 heads.) Every 2 or 3 days after the start of the administration, the state of hair development in the shavn area was scored in accordance with the following criteria.
Criteria for scoring the hair development: 1 = No hair pment. 2 = Hair development in less than 30% of the shaven area. 3 = Hair development in at least 30% but less than 60% of the shaven area. 4 = Hair pment in at least 60% but less than 90% of the shaven area.
= Hair development in at least 90% of the shaven area.
Results As Fig. 1 shows, the group administered with the solution of 5% nd 1 had their hair development scores increased earlier than the group administered with the base.
The hair development scores in the Compound 1 administered group were higher than those in the base administered group at day 15 of the administration and onward in the test period.
It threfore became clear that the test nd showed 'a superior hair pment ating effect. Such superior hair development stimulating effect is exhibited by the combination of various properties including not only the rotamase inhibiting effect of the compound but also its good stability, absorbability, and disposition.
(Test 4) Dissolution Test To 79 mL of ethanol, water was added to give a total volume of 100 mL, whereby a base was prepared. An excess amount of a test compound was put into a test tube, the prepared base was added, and the mixture was stirred at 5°C for 3 days and passed through a membrane filter (0.45 um); the resulting filtrate was diluted with acetonitrile and the concentration ofthe diluted solution was measured by HPLC to ine the lity of the compound. nd 40 had a solubility of 113.2 mg/mL.
(Test 5) Test for Measuring Hair Development Stimulating Effect in Shaven Mouse Model C57BL mice (female, ca. 7-wk old) were Shaven on the back and the base prepared in Test 4 or a solution prepared by dissolving 5% (w/v) of Compound 40 in this base was administered by applying them to the Shaven area in 200-uL portions once daily starting 3 days after the shaving (each group consisting of 10 heads.) Every 2 or 3 days after the start of the administration, the state of hair development in the shavn area was scored in accordance with the criteria described in Test 3.
Results As Fig. 2 shows, the group administered with the solution of 5% Compound 40 had their hair pment scores increased earlier than the group administered with the base. -86— The hair development scores in the Compound 40 administered group were higher than those in the base administered group at day 15 of the administration and onward in the test period.
It threfore became clear that the test compound showed a superior hair development stimulating effect.
The superior hair development stimulating effect of Compound 40 is ted by the combination of various properties including not only the rotamase inhibiting effect of the compound but also its good stability, absorbability, and ition.
(Test 6) Test for Measuring Anagen Induction Stimulating Effect in Shave Mouse Model Method It is known that as the hair cycle of the mouse skin makes a transition from the telogen to the anagen phase and as the anagen phae proceeds, the number of proliferating cell nuclear antigen (PCNA) positive cells in the hair follicle ses (Cravens et al., J.
Endocrinol. the increase in the ty of PCNA is one of , 191, 415-425, 2006) and, hence, the markers for the induction of the anagen phase.
The anagen induction stimulating effect of a compound was ed by the following method with the quantity of skin PCNA being used as an index.
C57BL mice (female, ca. 7-wk old) were shaven on the back and a base (80% ethanol) or a solution prepared by dissolving 5% (w/V) of Compound 40, 52, 59, 61, 63, 64 or 66 in this base was administered by applying them to the shaven area in 200-uL portions once daily for 2 days starting 3 days after the shaving (each group consisting of 5 heads.) About 4 hours after the administration on the second day, the skin at the application site was sampled and homogenized in a buffer containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP—40, and a protease inhibitor. By a centrifugal separation ure, a PCNA containing protein solution was prepared and the quantity of PCNA in the solution was measured with a PCNA—ELISA kit of chem, Inc.
BQSHJE As Fig. 3 shows, the group administered with Compound 40 which showed a hair development stimulating effect in Test 5 showd higher values for the ty of skin PCNA than the group administered with the base. It threfore became clear that the test ompound showed a superior anagen induction stimulating effect in the early stage ing the start of administration.
Like the group administered with Compound 40, the groups stered with the solutions of Compounds 52, 59, 61, 63, and 64 also showed increases in the quantity of skin PCNA. It threfore became clear that each of these compounds showed an anagen induction stimulating effect (Fig. 3.) [028 8] The same test was conducted on the group administered with Compound 66, which showed skin PCNA levels imately 1.4 times higher than those in the group administered with the base.
The superior anagen induction stimulating effect of these compounds is exhibited by the combination of various properties including not only the rotamase inhibiting effect of the compounds but also their good stability, absorbability, and disposition.
INDUSTRIAL APPLICABILITY The present invention enables providing novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of ia which comprise those compounds or pharmaceutically acceptable salts thereof.

Claims (19)

1. A compound represented by formula (1) [where R1 represents either the ing formula (2) or (3) ring A represents either one of the rings represented by the ing formula (4) X represents -(CH2)m-X1-(CH2)n-; X1 represents a bond, -O-, -NRaC(=O)-, -C(=O)NRb-, -NRcS(=O)2-, or 2NRd-; Ra, Rb, Rc, and Rd which may be the same or different each represent a hydrogen atom or a C1-6 alkyl group; m and n which may be the same or different each represent an integer of 0-3; R2 represents: an aryl group; a heteroaryl group, wherein said aryl or heteroaryl group may be substituted by 1-3 substituent groups selected from the group consisting of: a halogen atom, a C1-6 alkyl group, and a C1-6 alkoxy group, wherein said C1-6 alkyl group or C1-6 alkoxy group may be substituted by 1-3 substituent groups selected from the group consisting of a halogen atom and a hydroxy group; a 1,3-benzodioxolanyl group, an indolyl group, a morpholyl group, a hydroxy group, a C1-6 alkyl group wherein said C1-6 alkyl group may be substituted by 1-2 hydroxy an amino group, a mono-C1-6 mino group, a di-C1-6 alkylamino group, a C1-6 alkoxy group, a C1-6 alkylsulfonyloxy group, a pyridonyl group, or a pyrimidinonyl group, or a pharmaceutically acceptable salt thereof.
2. The compound or pharmaceutically acceptable salt thereof ing to claim 1, wherein X is a bond, -CH2O-, -CH2-, -(CH 2)2-, -(CH 2)3-, -O-, -CH2-NHC (=O )-, -CH 2-NHC (=O )-CH 2-, or -CH2-NHS (=O )2-.
3. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X is -CH2O- or –CH2-.
4. The compound or pharmaceutically acceptable salt thereof ing to any one of claims 1 to 3, wherein R1 is formula (2).
5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein ring A is either one of the rings of the following formula (5):
6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein R2 is: a phenyl group, a pyridyl group; a pyridazinyl group or a pyrimidyl group, wherein said phenyl group, pyridyl group or pyrimidyl group may be substituted by 1-3 halogen atoms or methoxy groups; a pyridonyl group; or a dinonyl group.
7. The compound or ceutically acceptable salt thereof according to claim 6, wherein R2 is a phenyl group or a pyridyl group, n said phenyl group or pyridyl group may be substituted by 1-3 methoxy groups.
8. The compound or ceutically acceptable salt thereof according to claim 1, wherein R1 is formula (2), ring A is either one of the rings of the following formula (5): X is -CH2O- or -(CH2)2-, R2 is a phenyl group or a pyridyl group wherein said phenyl group or pyridyl group may be substituted by 1-3 y groups.
9. The compound according to claim 1, which is (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )isoxazolyl )pyrrolidinyl )-2,2-difluoro(1- hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)-2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )(2-(5-((pyridin yloxy )methyl zolyl )pyrrolidinyl )ethanone, (S)-2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )(2-(5-((3,4,5- trimethoxyphenoxy )methyl )isoxazolyl )pyrrolidinyl )ethanone, ((3-(1-(2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )acetyl )pyrrolidin yl )isoxazolyl )methyl )benzamide, (S)-N-((3-(1-(2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )acetyl )pyrrolidin yl )isoxazolyl )methyl )benzenesulfonamide, (S)(2-(5-((dimethylamino )methyl )isoxazolyl )pyrrolidinyl )-2,2-difluoro(1- hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(1-((cyclohexylmethyl )sulfonyl )pyrrolidinyl ,4- dimethoxyphenoxy )methyl )isoxazole, (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )-1,3,4-oxadiazolyl )pyrrolidinyl )-2,2- ro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)-2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )(2-(5-(phenoxymethyl )- 1,3,4-oxadiazolyl lidinyl )ethanone, (S)-N-((5-(1-(2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )acetyl )pyrrolidin yl )-1,3,4-oxadiazolyl )methyl mide, (S)(2-(5-((dimethylamino l )-1,3,4-oxadiazolyl )pyrrolidinyl )-2,2-difluoro(1- hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(3-((3,4-dimethoxyphenoxy )methyl )-1,2,4-oxadiazolyl )pyrrolidinyl )-2,2- difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )methyl-1H-pyrazolyl )pyrrolidinyl )-2,2- difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(3-((3,4-dimethoxyphenoxy l )-isoxazolyl )pyrrolidinyl )-2,2-difluoro (1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )-1H-pyrazolyl )pyrrolidinyl )-2,2-difluoro- 2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )-1,3,4-thiadiazolyl )pyrrolidinyl )-2,2- difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )-4H-1,2,4-triazolyl )pyrrolidinyl )-2,2- ro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )methyl-1H-1,2,4-triazolyl )pyrrolidin yl )-2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )oxazolyl )pyrrolidinyl )-2,2-difluoro(1- hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )thiazolyl )pyrrolidinyl difluoro(1- hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, (S)-2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )(2-(5- (phenoxymethyl )isoxazolyl )pyrrolidinyl )ethanone, (S)-2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )(2-(5-((pyrimidin yloxy )methyl )isoxazolyl )pyrrolidinyl one, (S)((3-(1-(2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl l )pyrrolidin yl )isoxazolyl )methyl idin-4(1H )-one, (S)-2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )(2-(5-((pyrimidin yloxy )methyl )isoxazolyl )pyrrolidinyl )ethanone, (S)-2,2-difluoro(2-(5-((3-fluorophenoxy )methyl )isoxazolyl )pyrrolidinyl )(1- hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone, or ((3-(1-(2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )acetyl )pyrrolidin yl )isoxazolyl )methyl )pyridin-4(1H )-one, or a pharmaceutically acceptable salt thereof.
10. (S)(2-(5-((3,4-dimethoxyphenoxy )methyl )isoxazolyl )pyrrolidinyl )-2,2- difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl )ethanone ented by the following formula or a pharmaceutically acceptable salt f:
11. (S)(2-(5-((3,4-Dimethoxyphenoxy)methyl)-1,3,4-oxadiazolyl )pyrrolidinyl)- 2,2-difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)ethanone or a pharmaceutically acceptable salt thereof.
12. (S)-2,2-Difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)(2-(5-((3,4,5- trimethoxyphenoxy)methyl)isoxaolyl)pyrrolidinyl)ethanone represented by the following formula or a pharmaceutically acceptable salt f:
13. (S)-2,2-Difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)(2-(5-( phenoxymethyl)-1,3,4-oxadiazolyl)pyrrolidinyl)ethanone or a pharmaceutically acceptable salt thereof.
14. (S)-2,2-Difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)(2-(5-((pyridin yloxy)methyl)isoxazolyl)pyrrolidinyl)ethanone represented by the following formula or a pharmaceutically acceptable salt thereof:
15. 2-Difluoro(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)(2-(5-((pyridin yloxy)methyl)isoxazolyl)pyrrolidinyl)ethanone or a pharmaceutically acceptable salt thereof.
16. A compound represented by the ing formula or a pharmaceutically acceptable salt thereof: F O F N
17. A pharmaceutical comprising, as an active ingredient, the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16.
18. An agent for preventing or treating alopecia which comprises as an active ingredient the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to
19. The use of a compound according to any one of claims 1 to 16 in the manufacture of a medicament for the tion or treatment of alopecia.
NZ615210A 2011-03-15 2012-03-15 Azole derivative NZ615210B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011056149 2011-03-15
JP2011-056149 2011-03-15
PCT/JP2012/056624 WO2012124750A1 (en) 2011-03-15 2012-03-15 Azole derivative

Publications (2)

Publication Number Publication Date
NZ615210A NZ615210A (en) 2014-12-24
NZ615210B2 true NZ615210B2 (en) 2015-03-25

Family

ID=

Similar Documents

Publication Publication Date Title
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
EP3601216B1 (en) Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
EP3022202B1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
AU2012269648B2 (en) Therapeutically active compositions and their methods of use
EP2665362B1 (en) Olefin containing nuclear transport modulators and uses thereof
EP3684776B1 (en) Heterocyclyl substituted pyrrolopyridines that are inhibitors of the cdk12 kinase
EP2714681B1 (en) Substituted sulfonamides useful as antiapoptotic bcl inhibitors
EP3107898B1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
CA2917315A1 (en) Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
EP3448856B1 (en) 6-aminopyridin-3-yl thiazoles as modulators of ror gamma t
EP3438103B1 (en) Griseofulvin compound
WO2012174312A2 (en) Benzimidazole derivatives as antiviral agents
BR112020007967A2 (en) substituted imidazopyridine amides and use thereof
EP2687524B1 (en) Azole derivative
CN110088098B (en) Quinazolinone PARP-1 inhibitor and preparation method, pharmaceutical composition and application thereof
NZ615210B2 (en) Azole derivative
JP6020396B2 (en) Medicaments containing azole derivatives
CN114728917A (en) Oxamide derivative, preparation method and medical application thereof
WO2024026481A2 (en) Cdk2 inhibitors and methods of using the same
WO2024026483A2 (en) Cdk2 inhibitors and methods of using the same
WO2021102410A1 (en) Naphtho[2,1 -d]thiazole derivatives, compositions thereof and methods of treating disorders